Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Болезнь Паркинсона, вторичный паркинсонизм и другие заболевания, проявляющиеся синдромом паркинсонизма

Список литературы

  1. Schapira A.H., Jenner J. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011; №26(6):1049-55.
  2. Blauwendraat C., Nalls M.A., Singleton A.B. The genetic architecture of Parkinson's disease. Lancet Neurology 2020; №19(2):170-178.
  3. Saiki S., Sato S., Hattori N. Molecular pathogenesis of Parkinson's disease: update. J. Neurol. Neurosurg. Psychiatry 2012; №83 (4): 430–436.
  4. Gibb W.R.G., Lees A.J. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J. Neurol .Neurosurg. Psychiatry 1988; № 51 (6): 745-752.
  5. Höllerhage M. Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults. Neurobiol 2019; №149:377-418.
  6. Левин О.С. Сосудистый паркинсонизм: 20 лет спустя. РМЖ 2017; №21: с.1500-1506.
  7. Terashi H., Taguchi T., Aizawa H. Secondary parkinsonism. Nihon Rinsho 2017; №75 (1): 63-70.
  8. Coon E.A., Singer W. Synucleinopathies. Continuum 2020; №26(1):72-92.
  9. Kovacs G.G. Tauopathies. Clin Neurol 2017; №145: 355-368.
  10. McKeith I.G., Boeve B.F., Dickson D.W. et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology 2017; №89: c. 1–13.
  11. Lang A.E. Corticobasal degeneration: selected developments. Mov Disord 2003; №18 (6): 51-56.
  12. Twelves D., Perkins K.S., Counsell С. Systematic review of incidence studies of Parkinson's disease. MovDisord 2003; №18 (1): 19-31.
  13. Factor S. A., Weiner W.J. Parkinson's Disease. Diagnosis and Clinical Management. 2008; 819.
  14. Van Den Eeden S.K., Tanner C.M., Bernstein A.L. et al. lncidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity. Am J Epidemiol 2003; №157: 1015- 1022.
  15. Benito–León J., Bermejo-Pareja F., Morales-Gonzalez J.M. et al. Incidence of Parkinson disease and parkinsonism in three elderly populations of central Spain. Neurology 2004; 734-741.
  16. Baldereschi M., Di Carlo A., Vanni P., et al. Italian Longitudinal Study on Aging Working Group. Lifestyle-related risk factors for Parkinson's disease: a population-based study . Ada Neurol Scand 2003; №108: 10: 239-244.
  17. Wirdefeldt K., Adami H.O., Cole P., et al. Epidemiology and etiology of Parkinson’s disease: a review of the evidence. Eur J Epidemiol 2011; №26(1): 1-58.
  18. Hirtz D., Thurman D.J., Gwinn-Hardy K., et al. How common are the "common" neurologic disorders? Neurology 2007; № 68: 326-337.
  19. Гашилова Ф.Ф. Клинические и параклинические аспекты паркинсонизма в Томске. Автореферат дис... канд. мед. наук. Новосибирск, 2006.
  20. Докадина Л.В. Паркинсонизм: Клинико-эпидемиологические аспекты и состояние амбулаторной помощи на регионарном уровне. Автореферат дис... канд. мед. наук. М, 2004.
  21. Саютина С.Б., Валиулин М.А., Блохина И.А. Распространённость, диагностика и лечение болезни Паркинсона в Иркутской области. Руководство для врачей по материалам 1 Национального конгресса. М, 2008; 280 с.
  22. Страчунская Е.Я. Паркинсонизм с позиции современных информационных концепций медицины. Смоленск, 2008; 208 с.
  23. Campenhausen S., Bornschein B. Prevalence and incidence of Parkinson's disease in Europe. European Neuropsychopharmacology 2005; №15: 473-490.
  24. Pringsheim T., Jette N., Frolkis A. et al. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014; №29(13):1583-1590.
  25. Savica R., Grossardt B.R., Bower J. et al. Incidence and Time Trends of Drug- Induced Parkinsonism: A 30-Year Population-Based Study. Movement Disorders, 2017; №2: 227-234.
  26. Jellinger K.A. Vascular parkinsonism. Therapy 2008; № 5(2): 237–255.
  27. Van Zagten M., Lodder J., Kessels F. Gait disorder and parkinsonian signs in patients with stroke related to small deep infarcts and white matter lesions. Mov disord 1998; №13: 89– 95.
  28. Левин О.С. Экстрапирамидные синдромы при цереброваскулярных заболеваниях. Диагностика и лечение экстрапирамидных расстройств. Под ред. В.Н. Штока., И.А. Ивановой-Смоленской, О.С. Левина. М.: Медпресс-информ, 2003. с.503–519.
  29. Lo R.Y. Epidemiology of atypical parkinsonian syndromes. Tzu Chi Medical Journal 2021; 1-13.
  30. Fleury V., Brindel P., Nicastro N. et al. Descriptive epidemiology of parkinsonism in the Canton of Geneva, Switzerland. Parkinsonism Relat Disord 2018; № 54:30-39.
  31. Golbe L.I., Davis P.H., Schoenberg B.S. et al. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; №38 (7):1031-1034.
  32. Jankovic J. Parkinson’s disease: clinical features and diagnosis. Journal of Neurology, Neurosurgery & Psychiatry, 2008; №79(4): 368–376.
  33. Kim H., Mason S., Foltynie T. et al. Motor complications in Parkinson’s disease: 13‐ year follow‐up of the CamPaIGN cohort. Movement Disorders 2020; №35 (1): 185-190.
  34. Van Gilst M. M., Bloem B. R., Overeem S. “Sleep benefit” in Parkinson’s disease: A systematic review. Parkinsonism & Related Disorders 2013; №19(7): 654–659.
  35. Leentjens A.F.G., Dujardin K., Marsh L. et al. Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study. Parkinsonism & Related Disorders 2012; №18(10):1084-1088.
  36. Bronnick K., Ehrt U., Emre M., et al. Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. Neurol Neurosurg Psychiatry, 2006; №77 (10):1136-1142.
  37. Aarsland D., Marsh L., Schrag A. Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 2009; №24(15): 2175-2186.
  38. Williams-Gray C. H., Foltynie T., Brayne C.E. et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007; №130 (7):1787-1798.
  39. Ferman T.J., Smith G.E., Boeve B.F. et al. Neuropsychological differentiation of dementia with Lewy bodies from normal aging and Alzheimer's disease. The Clinical Neuropsychologist 2006; № 20(4): 623–636.
  40. McKeith I.G. Dementia with Lewy bodies: a clinical overview. Dementia CRC Press., 2017. c. 739–749.
  41. Thomas A.J., Taylor J.P., McKeith I. et al. Revision of assessment toolkits for improving the diagnosis of Lewy body dementia: The DIAMOND Lewy study. Int J Geriatr Psychiatry 2018; №33(10): 1293–1304.
  42. Wenning G.K., Geser F., Krismer F. et al. The natural history of multiple system atrophy: A prospective European cohort study. Lancet Neurol 2013; №12 (3):264-274.
  43. Low P.A., Reich S.G., Jankovic J. et al. Natural history of multiple system atrophy in the USA: A prospective cohort study. Lancet Neurol 2015; №14 (7):710-719.
  44. Nath U., Ben-Shlomo Y., Thomson R.G. et al. Clinical features and natural history of progressive supranuclear palsy: A clinical cohort study. Neurology 2003; №60 (6): 910-916.
  45. Glasmacher S.A., Leigh P.N., Saha R.A. Predictors of survival in progressive supranuclear palsy and multiple system atrophy: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2017; №88 (5): 402-411.
  46. Papapetropoulos S., Singer C., McCorquodale D. et al. Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 2005; №11 (7): 459-463.
  47. Postuma R.B. et al. MDS clinical diagnostic criteria for Parkinson’s disease // Mov. Disord. 2015. Vol. 30, № 12. P. 1591–1601.
  48. Руководство по диагностике и лечению болезни Паркинсона / под ред. Иллариошкина С.Н., Левина О.С. Москва: ООО "ИПК Парето-Принт, 2017. 336 с.
  49. Houlden H. et al. Multiple system atrophy: Genetic risks and alpha-synuclein mutations // F1000Research. 2017. Vol. 6, № 0. P. 1–10.
  50. Papay K. et al. Patient versus informant reporting of ICD symptoms in Parkinson’s disease using the QUIP: Validity and variability // Parkinsonism Relat. Disord. 2011. Vol. 17, № 3. P. 153–155.
  51. Pluim C.F. et al. Changes in Self- and Informant-Reported Frontal Behaviors in Parkinson’s Disease: A Longitudinal Study // J. Geriatr. Psychiatry Neurol. 2020. P. 089198872096425.
  52. Berardelli A. et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson’s disease // Eur. J. Neurol. 2013. Vol. 20, № 1. P. 16–34.
  53. Abraham D.S. et al. Annual Prevalence of Use of Potentially Inappropriate Medications for Treatment of Affective Disorders in Parkinson’s Disease // Am. J. Geriatr. Psychiatry. 2021. Vol. 29, № 1. P. 35–47.
  54. Baiano C. et al. Prevalence and Clinical Aspects of Mild Cognitive Impairment in Parkinson’s Disease: A Meta‐Analysis // Mov. Disord. 2020. Vol. 35, № 1. P. 45–54.
  55. Koerts J. et al. Working capacity of patients with Parkinson’s disease – A systematic review // Parkinsonism Relat. Disord. 2016. Vol. 27. P. 9–24.
  56. Hariz G.-M., Forsgren L. Activities of daily living and quality of life in persons with newly diagnosed Parkinson’s disease according to subtype of disease, and in comparison to healthy controls // Acta Neurol. Scand. 2011. Vol. 123, № 1. P. 20–27.
  57. Zhao N. et al. Quality of life in Parkinson’s disease: A systematic review and meta‐analysis of comparative studies // CNS Neurosci. Ther. 2021. Vol. 27, № 3. P. 270–279.
  58. Wang X. et al. Comorbidity burden of patients with Parkinson’s disease and Parkinsonism between 2003 and 2012: A multicentre, nationwide, retrospective study in China // Sci. Rep. 2017. Vol. 7, № 1. P. 1671.
  59. Santiago J.A., Bottero V., Potashkin J.A. Biological and Clinical Implications of Comorbidities in Parkinson’s Disease // Front. Aging Neurosci. 2017. Vol. 9.
  60. Bajaj S. et al. Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis // PLoS One / ed. Kassubek J. 2017. Vol. 12, № 12. P. e0189897.
  61. Zhang K. et al. Diagnostic validity of magnetic resonance parkinsonism index in differentiating patients with progressive supranuclear palsy from patients with Parkinson’s disease // Parkinsonism Relat. Disord. 2019. Vol. 66. P. 176–181.
  62. Schwarz S.T. et al. The ‘Swallow Tail’ Appearance of the Healthy Nigrosome – A New Accurate Test of Parkinson’s Disease: A Case-Control and Retrospective Cross-Sectional MRI Study at 3T // PLoS One / ed. Bush A.I. 2014. Vol. 9, № 4. P. e93814.
  63. Shafieesabet A. et al. Hyperechogenicity of substantia nigra for differential diagnosis of Parkinson’s disease: A meta-analysis // Parkinsonism Relat. Disord. 2017. Vol. 42. P. 1–11.
  64. Zhou H.Y. et al. The role of substantia nigra sonography in the differentiation of Parkinson’s disease and multiple system atrophy // Transl. Neurodegener. Translational Neurodegeneration, 2018. Vol. 7, № 1. P. 1–7.
  65. Heiss W.-D., Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson’s disease // Eur. J. Neurol. 2004. Vol. 11, № 1. P. 5–12.
  66. Booth T.C. et al. The Role of Functional Dopamine-Transporter SPECT Imaging in Parkinsonian Syndromes, Part 1 // Am. J. Neuroradiol. 2015. Vol. 36, № 2. P. 229–235.
  67. Clarke C.E., Davies P. Systematic review of acute levodopa and apomorphine challenge tests in the diagnosis of idiopathic Parkinson’s disease // J. Neurol. Neurosurg. & Psychiatry. 2000. Vol. 69, № 5. P. 590 LP – 594.
  68. Li K. et al. Diagnostic accuracy of REM sleep behaviour disorder screening questionnaire: a meta-analysis // Neurol. Sci. 2017. Vol. 38, № 6. P. 1039–1046.
  69. Chahine L.M., Amara A.W., Videnovic A. A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015 // Sleep Med. Rev. 2017. Vol. 35. P. 33–50.
  70. Zhang Y. et al. Sleep in Parkinson’s disease: A systematic review and meta- analysis of polysomnographic findings // Sleep Med. Rev. 2020. Vol. 51. P. 101281.
  71. Broen M.P.G. et al. Prevalence of anxiety in Parkinson’s disease: A systematic review and meta‐analysis // Mov. Disord. 2016. Vol. 31, № 8. P. 1125–1133.
  72. Reijnders J.S.A.M. et al. A systematic review of prevalence studies of depression in Parkinson’s disease // Mov. Disord. 2008. Vol. 23, № 2. P. 183–189.
  73. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease. Mov Disord 2018; 33:1248.
  74. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease N Engl J Med 1989; 321: 1364–1371.
  75. Palhagen S, Heinonen EH, Hagglund J, et al. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group. Neurology 1998; 51: 520–525.
  76. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937–1943.
  77. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004; 61: 561–566.
  78. Olanow CW, Rascol O, Hauser R, et al. A double blind, delayed-start trial of rasagiline in Parkinson’sdisease. N Engl J Med 2009; 361: 1268–1278.
  79. Oertel WH et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: The PELMOPET study. Movement Disorders 2006; 21.-№3: 343-353.
  80. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002; 287: 1653–1661.
  81. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five- year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484–1491.
  82. Whone AL, Watts RL, Stoessl AJ, et al. REAL-PET Study Group. Slower progression of Parkinson’s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003; 54: 93–101
  83. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006; 21: 343–353.
  84. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease. The Parkinson Study Group. N Engl J Med 2004; 351: 2498–2508.
  85. Quinn N, Critchley P, Marsden CD. Young onset Parkinson's disease. Mov Disord 1987; 2:73.
  86. Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005; 20:342.
  87. Rajput AH. Levodopa prolongs life expectancy and is non-toxic to substantia nigra. Parkinsonism Relat Disord 2001; 8: 95–100.
  88. Jankovic J, Hunter C. A double-blind, placebo -controlled and longitudinal study of riluzole in early Parkinson’s disease. Parkinsonism Relat Disord 2002; 8: 271–276.
  89. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. The Parkinson Study Group. Arch Neurol 2002; 59: 1541–1550.
  90. Nutt JG, Burchiel KJ, Comella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. The ICV GDNF Study Group. Neurology 2003; 60: 69–73.
  91. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group. JAMA 2000; 284: 1931–1938.
  92. Watts RL, Lyons KE, Pahwa R, et al. Onset of dyskinesia with adjunct ropinirole prolonged-release or additional levodopa in early Parkinson’s disease. Mov Disord 2010; 25: 858–866.
  93. Bracco F, Battaglia A, Chouza C, et al. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. PKDS009 Study Group. CNS Drugs 2004; 18: 733–746.
  94. Etminan M, Samii A, Takkouche B, Rochon PA. Increased risk of somnolence with the new dopamine agonists in patients with Parkinson’s disease: a meta-analysis of randomised controlled trials. Drug Saf 2001; 24: 863–868.
  95. Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments in Parkinson’s disease: incidence, neurobiological basis, management and prevention. Drug Saf 2009; 32: 475–488.Rektorova I, Rektor I, Bares M, et al. Pramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized study. Eur J Neurol 2003; 10: 399–406.
  96. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573–580.
  97. Leentjens AF The role of Dopamine Agonists with Parkinson’s disease. Drugs 2011; 71.-№3: 273-286.
  98. Van Camp G, Flamez A, Cosyns B, et al. Treatment of Parkinson’s disease with pergolide and relation to restrictive valvular heart disease. Lancet 2004; 363: 1179–1183.
  99. Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson’s disease. Lancet Neurol 2007; 6: 826–829.
  100. Katzenschlager R, Head J, Schrag A, et al. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008; 71:474.
  101. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009; 66:563.
  102. PD Med Collaborative Group, Gray R, Ives N, et al. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. Lancet 2014; 384:1196.
  103. Bergamasco B, Frattola L, Muratorio A, Piccoli F,Mailland F, Parnetti L. Alpha- dihydroergocryptine in he treatment of de novo parkinsonian patients: results of a multicentre, randomized, double-blind, placebo-controlled study. Acta Neurol Scand 2000; 101: 372–380.
  104. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999; 53: 573–579.
  105. Shannon KM, Bennett JP Jr, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. The Pramipexole Study Group. Neurology 1997; 49: 724–728.
  106. Kieburtz K. Parkinson Study Group PramiBID Investigators. Twice-daily, low- dose pramipexole in early Parkinson’s disease: a randomized, placebo-controlled trial. Mov Disord 2011; 26: 37–44.
  107. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson’s disease. The Ropinirole Study Group. Neurology 1997; 49: 393–399.
  108. Rascol O, Dubois B, Caldas AC, Senn S, Del Signore S, Lees A. Early piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN study. The Parkinson REGAIN Study Group. Mov Disord 2006; 21: 2110–2115.
  109. Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AH. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007; 22: 2398–2404.
  110. Jankovic J, Watts RL, Martin W, Boroojerdi B. Transdermal rotigotine: double- blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007; 64: 676–682
  111. Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson’s disease. Arch Neurol 2003; 60: 1721–1728.
  112. Oertel WH, Wolters E, Sampaio C, et al. Pergolide versus levodopa monotherapy in early Parkinson’s disease patients: the PELMOPET study. Mov Disord 2006; 21: 343–353.
  113. Parkinson’s Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson’s disease: three year interim report. BMJ 1993; 307: 469–472.
  114. Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson’s disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord 1998; 13: 46–51.
  115. Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson’s disease. The 053 Study Group. Neurology 1999; 53: 364–370.
  116. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson’s disease. Neurology 1995; 45: S13–S21.
  117. Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L. Ease-PD Monotherapy Study Investigators. Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson’s disease: a randomized, double-blind, non-inferiority crossover study. Curr Med Res Opin 2008; 24: 2883–2895.
  118. Hauser RA, Schapira AH, Rascol O, et al. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson’s disease. Mov Disord 2010; 25: 2542–2549.
  119. Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA. A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 2001; 58: 1385–1392.
  120. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. International Pramipexole- Bromocriptine Study Group. Neurology 1997; 49: 1060–1065.
  121. Mizuno Y, Yanagisawa N, Kuno S, et al. Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson’s disease. The Japanese Pramipexole Study Group. Mov Disord 2003;18: 1149–1156.
  122. Hutton JT, Koller WC, Ahlskog JE, et al. Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson’s disease. Neurology 1996; 46: 1062– 1065.
  123. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo- controlled trial of pergolide as an adjunct to Sinemet in Parkinson’s disease. Mov Disord 1994; 9: 40–47.
  124. Ziegler M, Castro-Caldas A, Del Signore S, Rascol O. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson’s disease: a 6-month, randomized, placebo-controlled study. Mov Disord 2003; 18: 418–425.
  125. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non- ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999; 66: 436–441.
  126. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J Neurol Neurosurg Psychiatry 2002; 72: 713–720.
  127. Moller JC, Oertel WH, Koster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord 2005; 20: 602–610.
  128. Mizuno Y, Abe T, Hasegawa K, et al. Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson’s disease: STRONG study. The STRONG Study Group. Mov Disord 2007; 22:1860–1865.
  129. Trenkwalder C, Kies B, Rudzinska M, et al. The RECOVER Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double- blind, randomized, placebo-controlled study (RECOVER). Mov Disord 2011; 26: 90–99
  130. Hely MA, Morris JG, Reid WG, et al. The Sydney Multicentre Study of Parkinson’s disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. J Neurol Neurosurg Psychiatry 1994; 57: 903– 910.
  131. Jorgensen PB, Bergin JD, Haas L, et al. Controlled trial of amantadine hydrochloride in Parkinson’s disease. N Z Med J 1971; 73: 263–267.
  132. Goetz CG, Shannon KM, Tanner CM, Carroll VS, Klawans HL. Agonist substitution in advanced Parkinson’s disease. Neurology 1989; 39: 1121–1122.
  133. Goetz CG, Blasucci L, Stebbins GT. Switching dopamine agonists in advanced Parkinson’s disease: is rapid titration preferable to slow? Neurology 1999; 52: 1227–1229.
  134. Canesi M, Antonini A, Mariani CB, et al. An overnight switch to ropinirole therapy in patients with Parkinson’s disease. Short communication. J Neural Transm 1999; 106: 925–929.
  135. Gimenez-Roldan S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson’s disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 2001; 24: 346–351.
  136. Chen X, Ren C, Li J, Wang S, Dron L, Harari O, Whittington C. The Efficacy and Safety of Piribedil Relative to Pramipexole for the Treatment of Early Parkinson Disease: A Systematic Literature Review and Network Meta-Analysis. Clin Neuropharmacol. 2020 Jul/Aug;43(4):100-106
  137. Reichmann H, Herting B, Miller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm 2003; 110: 1393–1400.
  138. Grosset K, Needleman F, Macphee G, Grosset D. Switching from ergot to nonergot dopamine agonists in Parkinson’s disease: a clinical series and five-drug dose conversion table. Mov Disord 2004; 19: 1370–1374.
  139. Lewitt PA, Boroojerdi B, Macmahon D, Patton J, Jankovic J. Overnight switch from oral dopaminergic agonists to transdermal rotigotine patch in subjects with Parkinson disease. Clin Neuropharmacol 2007; 30: 256–265.
  140. Linazasoro G. Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson’s disease. Spanish Dopamine Agonists Study Group. J Neurol 2004; 251: 335–339.
  141. Rascol O, Barone P, Hauser RA, et al. Efficacy, safety, and tolerability of overnight switching from immediatet o once daily extended-release pramipexole in early Parkinson’s disease. The Pramipexole Switch Study Group. Mov Disord 2010; 25: 2326–2332.
  142. Koller WC, Hutton JT, Tolosa E, Capilldeo R. Immediate-release and controlled- release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 1999; 53: 1012–1019.
  143. Goetz CG, Tanner CM, Shannon KM, et al. Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson’s disease patients with and without motor fluctuations. Neurology 1988; 38: 1143–1146.
  144. Lees AJ. A sustained-release formulation of L-dopa (Madopar HBS) in the treatment of nocturnal and early-morning disabilities in Parkinson’s disease. Eur Neurol 1987; 27(Suppl. 1): 126–134.
  145. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson’s disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997; 37: 23–27.
  146. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010; 68: 18–27.
  147. Parkes JD, Baxter RC, Marsden CD, Rees JE. Comparative trial of benzhexol, amantadine, and levodopa in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 1974; 37: 422–426.
  148. Goetz CG, Koller WC, Poewe W, et al. Management of Parkinson’s disease: an evidence-based review. Mov Disord 2002; 17(Suppl. 4): S1–S166.
  149. Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database Syst Rev 2003; 2:CD003735.
  150. Lees A.J. The on-off phenomenon. Journal of Neurology, Neurosurgery, Psychiatry 1989; 52: 29-37.
  151. Brooks DJ, Sagar H. UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson’s disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry 2003; 74: 1071–1079.
  152. Fung VS, Herawati L, Wan Y. Movement Disorder Society of Australia Clinical Research and Trials Group, QUEST-AP Study Group. Quality of life in early Parkinson’s disease treated with levodopa/carbidopa/entacapone. Mov Disord 2009; 24: 25–31.
  153. Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early Parkinson’s disease. The FIRST-STEP Study Group. Mov Disord 2009; 24: 541–550
  154. Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD. Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag. 2018 Apr 16;14:709-719. doi: 10.2147/TCRM.S163190. PMID: 29713179; PMCID: PMC5907888.
  155. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071- 9. doi: 10.1136/jnnp.74.8.1071. PMID: 12876237; PMCID: PMC1738605.
  156. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. doi: 10.1034/j.1600- 0404.2002.1o174.x. PMID: 11939936.
  157. Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol. 2001 Jan;8(1):53-60. doi: 10.1046/j.1468-1331.2001.00168.x. PMID: 11509081.
  158. Chang Y, Wang LB, Li D, Lei K, Liu SY. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis. Ann Med. 2017 Aug;49(5):421-434. doi: 10.1080/07853890.2017.1293285. Epub 2017 Mar 15. PMID: 28293967.
  159. Mínguez-Mínguez S, Solís-García Del Pozo J, Jordán J. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data. Pharmacol Res. 2013 Aug;74:78-86. doi: 10.1016/j.phrs.2013.05.005. Epub 2013 Jun 2. PMID: 23735235.
  160. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E; LARGO study group. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005 Mar 12- 18;365(9463):947-54. doi: 10.1016/S0140-6736(05)71083-7. PMID: 15766996.
  161. Binde CD, Tvete IF, Gåsemyr JI, Natvig B, Klemp M. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol. 2020 Dec;76(12):1731- 1743. doi: 10.1007/s00228-020-02961-6. Epub 2020 Jul 24. PMID: 32710141; PMCID: PMC7661406.
  162. Clarke C E, Speller J M, Clarke J A. Pramipexole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2000;(3):CD002261. doi: 10.1002/14651858.CD002261. PMID: 10908540.
  163. Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2001;(1):CD001516. doi: 10.1002/14651858.CD001516. PMID: 11279718.
  164. Rascol O, Lees AJ, Senard JM, Pirtosek Z, Montastruc JL, Fuell D. Ropinirole in the treatment of levodopa- induced motor fluctuations in patients with Parkinson’s disease. Clin Neuropharmacol 1996; 19: 234–245.
  165. Lieberman A, Olanow CW, Sethi K, et al. A multicen- ter trial of ropinirole as adjunct treatment for Parkin- son’s disease. Ropinirole Study Group. Neurology 1998; 51: 1057– 1062.
  166. Hersh BP, Earl NL, Hauser RA, Stacy M. Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations. Mov Disord. 2010 May 15;25(7):927-31. doi: 10.1002/mds.23040. PMID: 20461810.
  167. Pahwa R, Stacy MA, Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 1108–1115
  168. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W; Pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson disease: a randomized controlled trial. Neurology. 2011 Aug 23;77(8):767-74. doi: 10.1212/WNL.0b013e31822affdb. Epub 2011 Aug 10. PMID: 21832216.
  169. Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial. Mov Disord. 2005 May;20(5):602-10. doi: 10.1002/mds.20397. PMID: 15726540.
  170. Nomoto M, Mizuno Y, Kondo T, Hasegawa K, Murata M, Takeuchi M, Ikeda J, Tomida T, Hattori N. Transdermal rotigotine in advanced Parkinson's disease: a randomized, double-blind, placebo-controlled trial. J Neurol. 2014 Oct;261(10):1887-93. doi: 10.1007/s00415-014-7427-3. Epub 2014 Jul 15. PMID: 25022939.
  171. LeWitt PA, Poewe W, Elmer LW, Asgharnejad M, Boroojerdi B, Grieger F, Bauer L. The Efficacy Profile of Rotigotine During the Waking Hours in Patients With Advanced Parkinson's Disease: A Post Hoc Analysis. Clin Neuropharmacol. 2016 Mar- Apr;39(2):88-93. doi: 10.1097/WNF.0000000000000133. PMID: 26882318; PMCID: PMC4791317.
  172. LeWitt PA, Lyons KE, Pahwa R; SP 650 Study Group. Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology. 2007 Apr 17;68(16):1262-7. doi: 10.1212/01.wnl.0000259516.61938.bb. PMID: 17438216.
  173. Zhao H, Ning Y, Cooper J, Refoios Camejo R, Ni X, Yi B, Parks D. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. Adv Ther. 2019 Jun;36(6):1252-1265. doi: 10.1007/s12325-019-00938-1. Epub 2019 Apr 8. PMID: 30963514.
  174. Clarke C E, Speller J M, Clarke J A. Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2000; (3):CD002259. doi: 10.1002/14651858.CD002259. PMID: 10908539.
  175. Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B; SP 515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. 2007 Jun;6(6):513-20. doi: 10.1016/S1474-4422(07)70108-4. PMID: 17509486.
  176. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole- Bromocriptine Study Group. Neurology. 1997 Oct;49(4):1060-5. doi: 10.1212/wnl.49.4.1060. PMID: 9339690.
  177. Kulisevsky J, Pagonabarraga J. Tolerability and safety of ropinirole versus other dopamine agonists and levodopa in the treatment of Parkinson's disease: meta-analysis of randomized controlled trials. Drug Saf. 2010 Feb 1;33(2):147-61. doi: 10.2165/11319860- 000000000-00000. PMID: 20082541.
  178. Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate- to extended-release pramipexole in advanced Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):180-7. doi: 10.1111/j.1468-1331.2012.03822.x. Epub 2012 Jul 31. PMID: 22845710.
  179. Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W; Pramipexole ER Study Group. Efficacy and safety of extended- versus immediate-release pramipexole in Japanese patients with advanced and L-dopa-undertreated Parkinson disease: a double-blind, randomized trial. Clin Neuropharmacol. 2012 Jul-Aug;35(4):174-81. doi: 10.1097/WNF.0b013e31825f77b9. PMID: 22801294.
  180. Wang Y, Sun SG, Zhu SQ, Liu CF, Liu YM, Di Q, Shang HF, Ren Y, Xiang W, Chen SD. Analysis of pramipexole dose-response relationships in Parkinson's disease. Drug Des Devel Ther. 2016 Dec 23;11:83-89. doi: 10.2147/DDDT.S112723. PMID: 28096656; PMCID: PMC5207331.
  181. Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis. Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742- 1241.2009.02027.x. Epub 2009 Feb 16. PMID: 19222614.
  182. Stowe R, Ives N, Clarke CE, Deane K; van Hilten, Wheatley K, Gray R, Handley K, Furmston A. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166. doi: 10.1002/14651858.CD007166.pub2. PMID: 20614454.
  183. Yi ZM, Qiu TT, Zhang Y, Liu N, Zhai SD. Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation. Ther Clin Risk Manag. 2018 Apr 16;14:709-719. doi: 10.2147/TCRM.S163190. PMID: 29713179; PMCID: PMC5907888.
  184. Li J, Lou Z, Liu X, Sun Y, Chen J. Efficacy and Safety of Adjuvant Treatment with Entacapone in Advanced Parkinson's Disease with Motor Fluctuation: A Systematic Meta- Analysis. Eur Neurol. 2017;78(3-4):143-153. doi: 10.1159/000479555. Epub 2017 Aug 16. PMID: 28813703.
  185. Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M. A systematic review of catechol- 0-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol. 2012 Jul-Aug;35(4):185-90. doi: 10.1097/WNF.0b013e31825c034a. PMID: 22805229.
  186. Deane KH, Spieker S, Clarke CE. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004554. doi: 10.1002/14651858.CD004554.pub2. PMID: 15495119.
  187. Brooks DJ, Sagar H; UK-Irish Entacapone Study Group. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study. J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071- 9. doi: 10.1136/jnnp.74.8.1071. PMID: 12876237; PMCID: PMC1738605.
  188. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M; Celomen Study Group. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. 2002 Apr;105(4):245-55. doi: 10.1034/j.1600- 0404.2002.1o174.x. PMID: 11939936.
  189. Myllylä VV, Kultalahti ER, Haapaniemi H, Leinonen M; FILOMEN Study Group. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol. 2001 Jan;8(1):53-60. doi: 10.1046/j.1468-1331.2001.00168.x. PMID: 11509081.
  190. Armstrong M, Okun M. Diagnostic and Treatment of Parkinson Disease. A Rewiew. JAMA 2020; 323(6):546-560.
  191. Левин О.С., Федорова Н.В. Москва, Медпресс, 4-е издание, 2014 г.
  192. Balestrino R., Schapira A.H.V. Parkinson Disease .Europien Journal of Neuropogy 2020, 27:27-42.
  193. Olanow C.W., Kieburtz K., Odin P. et all. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advances Parkinson’s disease% a randomized, controlled, double-blined, double-dummy study. Lancet Neurol. 2014 Feb;13(2):141-9.
  194. Antonini A., Marano P. et all. Long-term effectiveness of levodopa-carbidopa intestinal gel on motor and non-motor symptoms in advanced Parkinson’s disease: result of the Italian GLORIA patient population. Neurological Sciences, 2020, 41:2929-2937.
  195. Antonini A. et all. The Tandem investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel (LCIG) in advanced Parkinson’s disease patients. Journal of Neural Transmission, 2020. 127: 881-891.
  196. Honig H., Antonini A. et all. Intrajejunal levodopa infusion in Parkinson’s disease: a pilot multicentral study of effects on nonmotor symptoms and quality of life. Movement disorders. Vol..24, No 10, 2009, 1468-1474.
  197. Zhang XR, Jiang ZY, Zhang ZR, Chen HJ, Wu K, He JC, Xie CL. The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review. Drug Des Devel Ther. 2020 Feb 26;14:845-854. doi: 10.2147/DDDT.S229621. PMID: 32161444; PMCID: PMC7050037.
  198. Marsili L, Bologna M, Miyasaki JM, Colosimo C. Parkinson's disease advanced therapies - A systematic review: More unanswered questions than guidance. Parkinsonism Relat Disord. 2021 Feb;83:132-139. doi: 10.1016/j.parkreldis.2020.10.042. Epub 2020 Nov 2. PMID: 33158747.
  199. Wang L, Li J, Chen J. Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis. Front Neurol. 2018 Jul 30;9:620. doi: 10.3389/fneur.2018.00620. PMID: 30104997; PMCID: PMC6077236.
  200. Wirdefeldt K, Odin P, Nyholm D. Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson's Disease: A Systematic Review. CNS Drugs. 2016 May;30(5):381-404. doi: 10.1007/s40263-016-0336-5. PMID: 27138916.
  201. Băjenaru O, Ene A, Popescu BO, Szász JA, Sabău M, Mureşan DF, Perju- Dumbrava L, Popescu CD, Constantinescu A, Buraga I, Simu M. The effect of levodopa- carbidopa intestinal gel infusion long-term therapy on motor complications in advanced Parkinson's disease: a multicenter Romanian experience. J Neural Transm (Vienna). 2016 Apr;123(4):407-14. doi: 10.1007/s00702-015-1496-z. Epub 2015 Dec 23. PMID: 26699635; PMCID: PMC4805768.
  202. Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, De Bie RMA, Kalia SK, Hodaie M, Munhoz RP, Fasano A, Lozano AM. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018 Apr;128(4):1199-1213. doi: 10.3171/2016.11.JNS16715. Epub 2017 Jun 30. PMID: 28665252.
  203. Tan ZG, Zhou Q, Huang T, Jiang Y. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clin Interv Aging. 2016 Jun 21;11:777-86. doi: 10.2147/CIA.S105505. PMID: 27382262; PMCID: PMC4922790.
  204. Xie CL, Shao B, Chen J, Zhou Y, Lin SY, Wang WW. Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple- treatments meta-analysas of randomized controlled trials. Sci Rep. 2016 May 4;6:25285. doi: 10.1038/srep25285. PMID: 27142183; PMCID: PMC4855136.
  205. Xu H, Zheng F, Krischek B, Ding W, Xiong C, Wang X, Niu C. Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review. J Int Med Res. 2017 Oct;45(5):1602-1612. doi: 10.1177/0300060517708102. Epub 2017 Jul 12. PMID: 28701061; PMCID: PMC5718722.
  206. Tambasco N., Romoli M., Calabresi P. Levodopa in Parkinson’s disease: current status and future developments. Current neuropharmacology. 2018; 16(8):1239-1252.
  207. Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High- dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol. 2003 May-Jun;26(3):146-50. doi: 10.1097/00002826-200305000-00008. PMID: 12782917.
  208. Giménez-Roldán S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol. 2001 Nov-Dec;24(6):346-51. doi: 10.1097/00002826-200111000-00006. PMID: 11801810.
  209. Pajo AT, Espiritu AI, Jamora RDG. Efficacy and safety of extended-release amantadine in levodopa-induced dyskinesias: a meta-analysis. Neurodegener Dis Manag. 2019 Aug;9(4):205-215. doi: 10.2217/nmt-2019-0011. Epub 2019 Aug 8. PMID: 31392922.
  210. Elahi B, Phielipp N, Chen R. N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol Sci. 2012 Jul;39(4):465-72. doi: 10.1017/s0317167100013974. PMID: 22728853.
  211. Sawada H, Oeda T, Kuno S, et al. Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PloS ONE 2010;5:e15298.
  212. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMAN- DYSK trial. Neurology 2014;82:300-307
  213. da Silva-Júnior FP, Braga-Neto P, Sueli Monte F, de Bruin VM. Amantadine reduces the duration of levodopa-induced dyskinesia: a randomized, double-blind, placebo- controlled study. Parkinsonism Relat Disord. 2005 Nov;11(7):449-52. doi: 10.1016/j.parkreldis.2005.05.008. Epub 2005 Sep 9. PMID: 16154788.
  214. Stathis P, Konitsiotis S, Tagaris G, Peterson D. Levetiracetam for the management of levodopa-induced dyskinesias in Parkinson’s disease. Mov Disord 2011;26:264-270.
  215. Durif F, Debilly B, Galitzky M, Morand D, Viallet F, Borg M, Thobois S, Broussolle E, Rascol O. Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study. Neurology. 2004 Feb 10;62(3):381-8. doi: 10.1212/01.wnl.0000110317.52453.6c. PMID: 14872017.
  216. Pierelli F, Adipietro A, Soldati G, Fattapposta F, Pozzessere G, Scoppetta C. Low dosage clozapine effects on L-dopa induced dyskinesias in parkinsonian patients. Acta Neurol Scand. 1998 May;97(5):295-9. doi: 10.1111/j.1600-0404.1998.tb05955.x. PMID: 9613557.
  217. Gomide L, Kummer A, Cardoso F, Teixeira AL. Use of clozapine in Brazilian patients with Parkinson's disease. Arq Neuropsiquiatr. 2008 Sep;66(3B):611-4. doi: 10.1590/s0004-282x2008000500001. PMID: 18949249.
  218. de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 Jan;70:55-59. doi: 10.1016/j.parkreldis.2019.12.011. Epub 2019 Dec 17. PMID: 31865063.
  219. Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, De Bie RMA, Kalia SK, Hodaie M, Munhoz RP, Fasano A, Lozano AM. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018 Apr;128(4):1199-1213. doi: 10.3171/2016.11.JNS16715. Epub 2017 Jun 30. PMID: 28665252.
  220. Tan ZG, Zhou Q, Huang T, Jiang Y. Efficacies of globus pallidus stimulation and subthalamic nucleus stimulation for advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clin Interv Aging. 2016 Jun 21;11:777-86. doi: 10.2147/CIA.S105505. PMID: 27382262; PMCID: PMC4922790.
  221. Xie CL, Shao B, Chen J, Zhou Y, Lin SY, Wang WW. Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple- treatments meta-analysas of randomized controlled trials. Sci Rep. 2016 May 4;6:25285. doi: 10.1038/srep25285. PMID: 27142183; PMCID: PMC4855136.
  222. Xu H, Zheng F, Krischek B, Ding W, Xiong C, Wang X, Niu C. Subthalamic nucleus and globus pallidus internus stimulation for the treatment of Parkinson's disease: A systematic review. J Int Med Res. 2017 Oct;45(5):1602-1612. doi: 10.1177/0300060517708102. Epub 2017 Jul 12. PMID: 28701061; PMCID: PMC5718722.
  223. DeMaagd G, Fhilip A. Parkinson’s disease and its management: part4: treatment of motor complications. Pharmacy and therapeutics. 2015; 40 (11) 747
  224. Koay L, Rose J, Abdelhafiz AH. Factors that lead to hospitalisation in patients with Parkinson disease-A systematic review. Int J Clin Pract. 2018 Jan;72(1). doi: 10.1111/ijcp.13039. Epub 2017 Nov 9. PMID: 29119656
  225. Simonet C, Tolosa E, Camara A, Valldeoriola F. Emergencies and critical issues in Parkinson's disease. Pract Neurol. 2020;20(1):15-25. doi:10.1136/practneurol-2018-002075
  226. Ghosh R, Liddle BJ. Emergency presentations of Parkinson's disease: early recognition and treatment are crucial for optimum outcome. Postgrad Med J. 2011 Feb;87(1024):125-31. doi: 10.1136/pgmj.2010.104976. Epub 2010 Nov 24. PMID: 21106801.
  227. Prasad S, Pal PK. When time is of the essence: Managing care in emergency situations in Parkinson's disease. Parkinsonism Relat Disord. 2019 Feb;59:49-56. doi: 10.1016/j.parkreldis.2018.09.016. Epub 2018 Sep 18. PMID: 30253924.
  228. Kaasinen V, Joutsa J, Noponen T, Päivärinta M. Akinetic crisis in Parkinson's disease is associated with a severe loss of striatal dopamine transporter function: a report of two cases. Case Rep Neurol. 2014 Nov 26;6(3):275-80. doi: 10.1159/000369448. PMID: 25566059; PMCID: PMC4280458.
  229. Bächli E, Albani C. Die akinetische Krise beim Morbus Parkinson [Akinetic crisis in Parkinson disease]. Schweiz Med Wochenschr. 1994 Jun 11;124(23):1017-23. German. PMID: 8023100.
  230. Wang M, Wang W, Gao Z, Yin X, Chen T, Jiang Z, Wang Z. Dyskinesia- hyperpyrexia syndrome in Parkinson's disease: a systematic review. Clin Auton Res. 2021 Apr 7. doi: 10.1007/s10286-021-00801-w. Epub ahead of print. PMID: 33826041.
  231. Temlett JA, Thompson PD. Reasons for admission to hospital for Parkinson's disease. Intern Med J. 2006 Aug;36(8):524-6. doi: 10.1111/j.1445-5994.2006.01123.x. PMID: 16866658.
  232. Chan DK, Cordato DJ, O'Rourke F. Management for motor and non-motor complications in late Parkinson's disease. Geriatrics. 2008 May;63(5):22-7. PMID: 18447408.
  233. Ebersbach G, Ip CW, Klebe S, Koschel J, Lorenzl S, Schrader C, Winkler C, Franke C. Management of delirium in Parkinson's disease. J Neural Transm (Vienna). 2019 Jul;126(7):905-912. doi: 10.1007/s00702-019-01980-7. Epub 2019 Feb 6. PMID: 30725186.
  234. Dag Aarsland, MD, PhD; Robert Perry, FrCPath; Jan P. Larsen, MD, PhD; Ian G. McKeith, FRCPysch; John T. O'Brien, MRCPsych; Elaine K. Perry, PhD; David Burn, MD; and Clive G. Ballard, MRCPsych, MD. Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. J Clin Psychiatry 2005;66(5):633-637
  235. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018 Jan 4;20(1):17r02185. doi: 10.4088/PCC.17r02185. PMID: 29325237.
  236. Lai CH, Yeh YC, Chen YY. Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism. Ther Adv Drug Saf. 2019 Jun 20;10:2042098619854007. doi: 10.1177/2042098619854007. PMID: 31258887; PMCID: PMC6587390.
  237. de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 Jan;70:55-59. doi: 10.1016/j.parkreldis.2019.12.011. Epub 2019 Dec 17. PMID: 31865063.
  238. Jeong S, Cho H, Kim YJ, Ma HI, Jang S. Drug-induced Parkinsonism: A strong predictor of idiopathic Parkinson's disease. PLoS One. 2021 Mar 1;16(3):e0247354. doi: 10.1371/journal.pone.0247354. PMID: 33647030; PMCID: PMC7920346.
  239. Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect. 1993;6(1):63-72. doi: 10.1007/BF02252624. PMID: 8105799.
  240. Ware MR, Feller DB, Hall KL. Neuroleptic Malignant Syndrome: Diagnosis and Management. Prim Care Companion CNS Disord. 2018 Jan 4;20(1):17r02185. doi: 10.4088/PCC.17r02185. PMID: 29325237.
  241. Onofrj M. et al. Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment //Parkinsonism & related disorders. – 2009. – Т. 15. C. S233-S236.
  242. Lee JY, Oh S, Kim JM, Kim JS, Oh E, Kim HT, Jeon BS, Cho JW. Intravenous amantadine on freezing of gait in Parkinson's disease: a randomized controlled trial. J Neurol. 2013 Dec;260(12):3030-8. doi: 10.1007/s00415-013-7108-7. Epub 2013 Sep 22. PMID: 24057149.
  243. Butzer JF, Silver DE, Sahs AL. Amantadine in Parkinson's disease. A double-blind, placebo-controlled, crossover study with long-term follow-up. Neurology. 1975 Jul;25(7):603-6. doi: 10.1212/wnl.25.7.603. PMID: 807867.
  244. Wang M, Wang W, Gao Z, Yin X, Chen T, Jiang Z, Wang Z. Dyskinesia- hyperpyrexia syndrome in Parkinson's disease: a systematic review. Clin Auton Res. 2021 Apr 7. doi: 10.1007/s10286-021-00801-w. Epub ahead of print. PMID: 33826041.
  245. Baek MS, Lee HW, Lyoo CH, Seok Baek M, Woo Lee H, Hyoung Lyoo C. A patient with recurrent dyskinesia and hyperpyrexia syndrome. JMD 2017;10:154–7.
  246. Crosby NJ, Deane KH, Clarke CE. Amantadine for dyskinesia in Parkinson's disease. Cochrane Database Syst Rev. 2003;(2):CD003467. doi: 10.1002/14651858.CD003467. PMID: 12804468.
  247. Kong M, Ba M, Ren C, Yu L, Dong S, Yu G, Liang H. An updated meta-analysis of amantadine for treating dyskinesia in Parkinson's disease. Oncotarget. 2017 May 5;8(34):57316-57326. doi: 10.18632/oncotarget.17622. PMID: 28915672; PMCID: PMC5593643.
  248. Sawada H, Oeda T, Kuno S, Nomoto M, Yamamoto K, Yamamoto M, Hisanaga K, Kawamura T; Amantadine Study Group. Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One. 2010 Dec 31;5(12):e15298. doi: 10.1371/journal.pone.0015298. PMID: 21217832; PMCID: PMC3013111.
  249. Del Dotto P, Pavese N, Gambaccini G, Bernardini S, Metman LV, Chase TN, Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double- blind placebo-controlled study. Mov Disord. 2001 May;16(3):515-20. doi: 10.1002/mds.1112. PMID: 11391748.
  250. Metman LV, Del Dotto P, LePoole K, Konitsiotis S, Fang J, Chase TN. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol. 1999 Nov;56(11):1383-6. doi: 10.1001/archneur.56.11.1383. PMID: 10555659.
  251. Widman LP, Burke WJ, Pfeiffer RF, McArthur-Campbell D. Use of clozapine to treat levodopa-induced psychosis in Parkinson's disease: retrospective review. J Geriatr Psychiatry Neurol. 1997 Apr;10(2):63-6. doi: 10.1177/089198879701000205. PMID: 9188021.
  252. Factor SA, Brown D. Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord. 1992;7(2):125-31. doi: 10.1002/mds.870070205. PMID: 1350059.
  253. Lonergan E, Britton AM, Luxenberg J, Wyller T (2007) Antipsychotics for delirium. Cochrane Database Syst Rev. https://doi. org/10.1002/14651858.CD005594.pub2
  254. Boettger S, Jenewein J, Breitbart W (2015) Haloperidol, risperidone, olanzapine and aripiprazole in the management of delirium: a comparison of efficacy, safety, and side effects. Palliat Support Care 13:1079–1085
  255. Dag Aarsland, MD, PhD; Robert Perry, FrCPath; Jan P. Larsen, MD, PhD; Ian G. McKeith, FRCPysch; John T. O'Brien, MRCPsych; Elaine K. Perry, PhD; David Burn, MD; and Clive G. Ballard, MRCPsych, MD. Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. J Clin Psychiatry 2005;66(5):633-637
  256. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzen- schlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sam- paio C (2011) The movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):42–80
  257. Inzellberg R., Bonuccelli U., Schechtman E. Association between amantadine and onset of dementia in Parkinson disease. Mov Disord.2006; 21(9):1375-9.
  258. Hanagasi H.A., Gurvit H., Unsalan P., et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo- controlled, multicenter study. Mov Disord. 2011;26(10):1851-8.
  259. Frakey L.L., Friedman J.H. Cognitive effects of rasagiline in mild‐to‐moderate stage Parkinson's disease without dementia. J Neuropsychiatry Clin Neurosci. 2017;29:22‐25.
  260. Скоромец А.А., Тимофеева А.А., Алиев К.Т. и др. Когнитивные функции при болезни Паркинсона и паркинсонизме, их коррекция пронораном. Эффективная фармакотерапия. 2014; N.17: С. 6-14.
  261. Begemann M. J., Brand B.A., Ćurčić-Blake B. et al. Efficacy of non-invasive brain stimulation on cognitive functioning in brain disorders: a meta-analysis. Psychol Med. 2020; 50(15):2465-2486.
  262. Biundo R., Weis L., Fiorenzato E. et al. Double‐blind randomized trial of tDCS versus sham in Parkinson patients with mild cognitive impairment receiving cognitive training. Brain Stim. 2015;8:1223‐1225.
  263. Nikolin S., Huggins C., Martin D. et al. Safety of repeated sessions of transcranial direct current stimulation: a systematic review. Brain Stim. 2018; 11:278‐288.
  264. Petersen R.C., Lopez O.L., Armstrong M.J. Practice guideline update summary: Mild cognitive impairment. Neurology. 2018; 90: 126 – 135.
  265. Ferreira J.J., Katzenschlager R., Bloem B. R. et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson's disease. Eur J Neurol. 2013; 20(1):5-15.
  266. Green A.R., Oh E., Hilson L. et al. Anticholinergic burden in older adults with mild cognitive impairment. J. Am. Geriatr. Soc. 2016; 64: 313 - e314.
  267. Ehrt U., Broich K., Larsen J.P. et al. Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. J Neurol Neurosurg Psychiatry. 2010; 81:160‐165.
  268. Song D., Yu D.S.F., Li P.W.C., Lei Y. The effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment: A systematic review and meta-analysis. Int J Nurs Stud. 2018; 79: с. 155 – 164.
  269. Northey J.M., Cherbuin N., Pumpa K.L. et al. Exercise interventions for cognitive function in adults older than 50: a systematic review with meta-analysis. Br J Sports Med. 2018; 52(3): с. 154 – 160.
  270. Murray D. K. The effects of exercise on cognition in Parkinson’s disease: a systematic review. Transl Neurodegener. 2014; 3(1): p. 5.
  271. Seppi K., Chaudhuri K.R., Coelho M. et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review. 34(2): 180–198. Mov Disord. 2019;
  272. Barha C.K., Davis J.C., Falck R.S. et al. Sex differences in exercise efficacy to improve cognition: A systematic review and meta-analysis of randomized controlled trials in older humans. Front Neuroendocrinol. 2017; 46: с. 71 - 85.
  273. Teixeira‐Machado L., Araujo F.M., Cunha F.A. et al. Feldenkrais method‐based exercise improves quality of life in individuals with Parkinson's disease: a controlled, randomized clinical trial. Altern Ther Health Med. 2015;21:8‐14.
  274. Chandler M.J., Parks A.C., Marsiske M. et al. Everyday Impact of Cognitive Interventions in Mild Cognitive Impairment: a Systematic Review and Meta-Analysis. Neuropsychol Rev. 2016; 26(3): с. 225 – 251.
  275. Hill N.T., Mowszowski L., Naismith S.L., et al. Computerized Cognitive Training in Older Adults With Mild Cognitive Impairment or Dementia: A Systematic Review and Meta-Analysis. Am J Psychiatry.2017; 174(4): с. 329 – 340.
  276. Leung I.H., Walton C.C., Hallock H. et al. Cognitive training in Parkinson disease: a systematic review and meta‐analysis. Neurology. 2015; 85:1843‐1851.
  277. Cerasa A., Gioia M.C., Salsone M. et al. Neurofunctional correlates of attention rehabilitation in Parkinson's disease: an explorative study. Neurological Sci. 2014;35:1173‐1180.
  278. Petrelli A., Kaesberg S., Barbe M.T. et al. Effects of cognitive training in Parkinson's disease: a randomized controlled trial. Parkinsonism Relat Disord .2014;20:1196‐ 1202.
  279. Alzahrani H., Venneri A. Cognitive rehabilitation in Parkinson’s disease: a systematic review. Journal of Parkinson’s Disease. 2018; 8(2):233–245.
  280. Mamikonyan E., Xie S.X., Melvin E., Weintraub D. Rivastigmine for mild cognitive impairment in Parkinson disease: A placebo-controlled study. Mov. Disord. 2015; 30:912–918.
  281. Baik K., Kim S.M., Jung J. H. et al. Donepezil for mild cognitive impairment in Parkinson's disease. Sci Rep. 2021;11(1):4734.
  282. Knight R., Khondoker M., Magill N. et al. A systematic review and meta-analysis of the effectiveness of acetylcholinesterase inhibitors and memantine in treating the cognitive symptoms of dementia. Dementia and Geriatric Cognitive Disorders. 2018; 45: с. 131 – 151.
  283. Rolinski M., Fox C., Maidment I., McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database Syst Rev. 2012;(3):CD006504.
  284. Wang H.‐F., Yu J.‐T., Tang S.‐W. et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta‐analysis and trial sequential analysis. J Neurol Neurosurg Psychiatry. 2015; 86:135‐143.
  285. Bohnen N. I., Kaufer D. I., Ivanco L. S. et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in alzheimer disease. Archives of Neurology. 2003; 60(12):1745–1748.
  286. Emre M., Aarsland D., Albanese A. et al. Rivastigmine for dementia associated with Parkinson’s disease. New England Journal of Medicine. 2004; 351(24):2509–2518.
  287. Dubois B., Tolosa E., Katzenschlager R. et al. Donepezil in Parkinson's disease dementia: a randomized, double‐blind efficacy and safety study. Mov Disord. 2012;27:1230‐ 1238.
  288. Aarsland D., Laake K., Larsen J.P., Janvin C. Donepezil for cognitive impairment in Parkinson’s disease: a randomised controlled study. J Neurol Neurosurg Psychiatry. 2002; 72: 708–712.
  289. Leroi I., Brandt J., Reich S.G. et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson’s disease. Int J Geriatr Psychiatry. 2004; 19: 1– 8.
  290. Litvinenko I.V., Odinak M.M., Mogil’naya V.I., Emelin A.Y. Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson’s disease (an open controlled trial). Neurosci Behav Physiol. 2008; 38: 937–945.
  291. Emre M., Poewe W., De Deyn P.P. et al. Long-term safety of rivastigmine in parkinson disease dementia: an open-label, randomized study. Clin Neuropharmacol. 2014;37(1):9–16.
  292. McShane_R., Westby_M.J., Roberts_E..et al. Memantine for dementia. Cochrane Database of Systematic Reviews. 2019; Issue 3. Art. No.: CD003154.
  293. Meng Y.-H., Wang P.-P., Song Y.-H., Wang J-H. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis Experimental and therapeutic medicine. 2019; (17): 1611-1624.
  294. Brennan L., Pantelyat A., Duda J.E. et al. Memantine and Cognition in Parkinson"s Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. Mov Disord Clin Pract. 2015; 3(2): с. 161 – 167.
  295. Wesnes K.A., Aarsland D., C., Londos E. Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. Int J Geriatr Psychiatry. 2015;30(1):46-54.
  296. Aarsland D., Ballard C., Walker Z. et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: A double-blind, placebo-controlled, multicentre trial. Lancet Neurol. 2009; 8: 613-618.
  297. Matsunaga S., Kishi T., Iwata N. Memantine for Lewy body disorders:systematic review and meta-analysis. Am J Geriatr Psychiatry. 2015; 23:373–383.
  298. Larsson V., Engedal K., Aarsland D. et al. Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia. Dement Geriatr Cogn Disord. 2011;32:227–234.
  299. Stubendorff K., Larsson V., Ballard C. et al. Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson’s disease with dementia: a prospective study. BMJ Open. 2014; 4:e005158.
  300. Marsh L., McDonald W.M., Cummings J., et.al. NINDS/NIMH Work Group on Depression and Parkinsons Disease. Provisional diagnostic criteria for depression in. Provisional diagnostic criteria for depression in Parkinsons Disease: report of an NINDS/NIMH Work Group. Mov.Dis.2006 ;21:148-158.
  301. Maricle RA, Nutt JG, Valentine RJ, Carter JH. Dose-response relationship of levodopa with mood and anxiety in fluctuating Parkinson’s disease: a double-blind, placebo- controlled study. Neurology. 1995;45:1757–1760.
  302. Witjas T, Kaphan E, Azulay JP, et al. Nonmotor fluctuations in Parkinson’s disease: frequent and disabling. Neurology. 2002;59:408–413.
  303. Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind,placebo-controlled trial. Lancet Neurol 2010; 9:573–580.
  304. Pahwa R., Stacy M.A., Factor S.A., Lyons K.E., et.al. Ropinirole 24-hour prolonged release.Randomized, controlled study in advanced Parkinson disease on behalf of the EASE-PD Adjunct Study Investigators. Neurology 2008;68:1108–1115.
  305. Barone P., Scarzella L., Antonini A. et al. Pramipexole versus sertraline in the treatment of depression in Parkinsons disease. J Neurol.2005; 4: 1—7.
  306. Barone P, Santangelo G, Morgante L, et al. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Euro J Neurol 2015;22:1184-1191.
  307. Chung SJ, Asgharnejad M, Bauer L, Ramirez F, Jeon B. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother 2016;17:1453-1461.
  308. Lemke M.R. Depressive symptoms in Parkinsons disease. Eur.J.of Neurol.2008;15(Suppl.1):21-25.
  309. Angelo Antonini , Silvana Tesei, Anna Zecchinelli, Paolo Barone, Danilo De Gaspari, Margherita Canesi, Giorgio Sacilotto, Nicoletta Meucci, Claudio Mariani, Gianni Pezzoli. Randomized study of sertraline and low-dose amitriptyline in patients with Parkinson's disease and depression: effect on quality of life. Mov Disord.2006 Aug;21(8):1119-22.
  310. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo- controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-1236.
  311. F. Fregni , C M Santos, M L Myczkowski, R Rigolino, J Gallucci-Neto, E R Barbosa, K D Valente, A Pascual-Leone, M A Marcolin. Repetitive transcranial magnetic stimulation is as effective as fluoxetine in the treatment of depression in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry. 2004 Aug;75(8):1171-4.
  312. David Devos , Kathy Dujardin, Isabelle Poirot, Caroline Moreau, Olivier Cottencin, Pierre Thomas, Alain Destée, Regis Bordet, Luc Defebvre Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: a double-blind, randomized, placebo-controlled study.Mov Disord. 2008 Apr 30;23(6):850-7.
  313. Menza M, Dobkin R, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009;72:886-892.
  314. Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence- based medicine review. Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Erratum in: Mov Disord. 2019 May;34(5):765. PMID: 30653247; PMCID: PMC6916382
  315. Makkos A, Pal E, Aschermann Z, et al. High-frequency repetitive transcranial magnetic stimulation can improve depression in Parkinson’s disease: a randomized, double- blind, placebo-controlled study. Neuropsychobiology 2016;73:169-177,
  316. Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psych 2011;168:1066- 1074.
  317. Makkos A, Pal E, Aschermann Z, et al. High-frequency repetitive transcranial magnetic stimulation can improve depression in Parkinson’s disease: a randomized, double- blind, placebo-controlled study. Neuropsychobiology 2016;73:169-177], КПТ[Dobkin RD, Menza M, Allen LA, et al. Cognitive-behavioral therapy for depression in Parkinson’s disease: a randomized, controlled trial. Am J Psych 2011;168:1066-1074.
  318. Lesenskyj AM, Samples MP, Farmer JM, Maxwell CR. Treating refractory depression in Parkinson's disease: a meta-analysis of transcranial magnetic stimulation. Transl Neurodegener. 2018 Mar 22;7:8. doi: 10.1186/s40035-018-0113-0.
  319. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.Brain 2013;136:1568-1577
  320. Leentjens A, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivotional symptoms in Parkinson disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89–92.
  321. Leentjens A, Koester J, Fruh B, et al. The effect of pramipexole on mood and motivotional symptoms in Parkinson disease: a meta-analysis of placebo-controlled studies. Clin Ther. 2009;31(1):89–92.
  322. Thobois S, Lhommee E, Klinger H, et al. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.Brain 2013;136:1568-1577.].
  323. Aarsland D, Mosimann UP, McKeith IG. Role of cholinesterase inhibitors in Parkinsons disease and dementia with Levy bodies. J Geriatr Psychiatry. 2000;15(5):387–92.
  324. Lim TT, Kluger BM, Rodriguez RL, et al. Rasagiline for the symptomatic treatment of fatigue in Parkinson’s disease. Mov Disord 2015;30:1825-1830.
  325. Нодель М.Р. , Яхно Н.Н. Утомляемость при болезни Паркинсона. Неврологический Журнал.2017;5:244-251.Siciliano M, Trojano L, Santangelo G, De Micco R, Tedeschi G, Tessitore A. Fatigue in Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2018 Nov;33(11):1712-1723. doi: 10.1002/mds.27461.
  326. Ortiz-Rubio A, Cabrera-Martos I, Torres-Sánchez I, Casilda-López J, López- López L, Valenza MC. Effects of a resistance training program on balance and fatigue perception in patients with Parkinson's disease: A randomized controlled trial. Med Clin (Barc). 2018 Jun 22;150(12):460-464. English, Spanish. doi: 10.1016/j.medcli.2017.10.022. Epub 2017 Nov 22. PMID: 29173985
  327. Leeman AL, O’Neill CJ, Nicholson PW, et al. Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987; 24: 637–643.
  328. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S. Sleep disorders in Parkinson’s disease. J Neurol1998; 45(Suppl. 1): S15–S18
  329. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 Jan;26(1):90-9/
  330. Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther. 2018 Jul 4;12:2017-2024
  331. Leeman AL, O’Neill CJ, Nicholson PW, et al. Parkinson’s disease in the elderly: response to and optimal spacing of night time dosing with levodopa. Br J Clin Pharmacol 1987; 24: 637–643.
  332. Xiang W, Sun YQ, Teoh HC. Comparison of nocturnal symptoms in advanced Parkinson's disease patients with sleep disturbances: pramipexole sustained release versus immediate release formulations. Drug Des Devel Ther. 2018 Jul 4;12:2017-2024],
  333. Ray Chaudhuri K, Martinez-Martin P, Rolfe K.A, Cooper J, Rockett CB, Giorgi L, Ondo WG. Improvements in nocturnal symptoms with ropinirole prolonged release in patients with advanced Parkinson's disease. Eur J Neurol. 2012 Jan; 19(1):105-13.
  334. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR; Recover Study Group. Rotigotine effects on early morning motor function and sleep in Parkinson's disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord. 2011 Jan;26(1):90-9. doi: 10.1002/mds.23441. Epub 2010 Nov 18. PMID: 21322021; PMCID: PMC3072524.
  335. Eggert K, Ohlwein C, Kassubek J, et al. Influence of the nonergot dopamine agonist piribedil on vigilance in patients With Parkinson Disease and excessive daytime sleepiness (PiViCog-PD): an 11-week randomized comparison trial against pramipexole and ropinirole. Clin Neuropharmacol 2014;37:116-122.
  336. Яхно Н.Н., Нодель М.Р., Федорова Н.В., Левин О.С., Артемьев Д.В., Смоленцева И.Г., Кулуа Т.К. Эффективность и переносимость препарата Сталево при болезни Паркинсона. Неврологический журнал. 2007. N 6. С. 48-52.
  337. Кулуа Т.К., Федорова Н.В., Поповкина O.A. Ночные моторные симптомы болезни Паркинсона и их коррекция трехкомпонентным препаратом леводопа/карбидопа/энтакапон. Журн. неврологии и психиатрии им. С.С.Корсакова. - 2011, № 9(2). С. 45-50.
  338. Park KW, Jo S, Lee SH, Hwang YS, Lee D, Ryu HS, Chung SJ. Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson's Disease. J Mov Disord. 2020 Sep;13(3):205-212.
  339. Videnovic A. Management of Sleep Disorders in Parkinsons Disease and multiple system atrophy. Movement Disorders 2017; 32(5):659-668.
  340. Dowling G., Mastick J., Colling E, et.al. Melatonin for sleep disturbances in in PD. Sleep Med. 2005;6:459-466. Medeiros CA. Carvalhedo de Bruin PF, Lopes LA,Magalhaes MC, de Lourdes Seabra M, Sales de Bruin VM. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254:459–464.
  341. Matthew Menza , Roseanne DeFronzo Dobkin, Humberto Marin, Michael Gara, Karina Bienfait, Allison Dicke, Cynthia L Comella, Charles Cantor, Lee Hyer. Treatment of insomnia in Parkinson's disease: a controlled trial of eszopiclone and placebo. Randomized Controlled Trial. Mov Disord. 2010 Aug 15;25(11):1708-14.
  342. Riemann D. et al. European guideline for the diagnosis and treatment of insomnia J Sleep Res. 2017 Dec;26(6):675-700
  343. Loddo G. et al. The treatment of sleep disorders in Parkinson’s disease: from research to clinical practice //Frontiers in neurology. – 2017. – Т. 8. C. 42.
  344. Yang H, Petrini M.Effect of cognitive behavior therapy on sleep disorder in Parkinson's disease in China: a pilot study.Nurs Health Sci. 2012 Dec;14(4):458-63.
  345. Nascimento CM, Ayan C, Cancela JM, Gobbi LT, Gobbi S, Stella F. Effect of a multimodal exercise program on sleep disturbances and instrumental activities of daily living performance on Parkinson's and Alzheimer's disease patients.Geriatr Gerontol Int. 2014 Apr;14(2):259-664.
  346. Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC. Timed Light Therapy for Sleep and Daytime Sleepiness Associated With Parkinson Disease: A Randomized Clinical Trial. JAMA Neurol. 2017 Apr 1;74(4):411-418].
  347. Carlos Mauricio Oliveira de Almeida , Daniela Vianna Pachito, Manoel Alves Sobreira-Neto, Vitor Tumas, Alan Luiz Eckeli. Pharmacological treatment for REM sleep behavior disorder in Parkinson disease and related conditions: A scoping review. J Neurol Sci. 2018 Oct 15;393:63-68.
  348. Moran Gilat, Alessandra Coeytaux Jackson, Nathaniel S Marshall, Deborah Hammond, Anna E Mullins, Julie M Hall, Bernard A M Fang, Brendon J Yee, Keith K H Wong , Ron R Grunstein, Simon J G Lewis. Melatonin for rapid eye movement sleep behavior disorder in Parkinson's disease: A randomised controlled trial. Mov Disord. 2020 Feb;35(2):344-349].
  349. Di Giacopo R, Fasano A, Quaranta D, Della Marca G, Bove F,Bentivoglio AR. Rivastigmine as alternative treatment for refractory REM behavior disorder in Parkinson’s disease. Mov Disord 2012;27:559-561.
  350. Paus S., Brecht H.M., Köster J. Sleep attacks, daytime sleepiness, and dopamine agonists in parkinson’s disease. Mov. Disord. 2003; 18 (6): 659–67.
  351. Neikrug AB, Liu L, Avanzino JA, Maglione JE, Natarajan L,Bradley L, et al. Continuous positive airway pressure improves sleep and daytime sleepiness in patients with Parkinson disease and sleep apnea. Sleep 2014;37:177-85.
  352. Papapetropoulos S, Mash DC. Psychotic symptoms in Parkinson's disease. From description to etiology. J Neurol. 2005 Jul;252(7):753-64. doi: 10.1007/s00415-005-0918-5. PMID: 15999234.
  353. Zahodne L. B., Fernandez H. H. Pathophysiology and treatment of psychosis in Parkinson’s disease //Drugs & aging. – 2008. – Т. 25. – №. 8. C. 665-682
  354. Pintor L, Valldeoriola F, Bailles E, Marti MJ, Muniz A, Tolosa E. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson disease: a randomized open clinical trial. Clin Neuropharmacol 2012;35:61-66.
  355. Sarah Horn , Hayley Richardson , Sharon X Xie , Daniel Weintraub , Nabila Dahodwala. Pimavanserin versus quetiapine for the treatment of psychosis in Parkinson's disease and dementia with Lewy bodies. Parkinsonism Relat Disord. 2019 Dec;69:119-124.
  356. David Burn , Murat Emre, Ian McKeith, Peter Paul De Deyn, Dag Aarsland, Chuanchieh Hsu, Roger Lane. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2006 Nov;21(11):1899-907
  357. Yoon-Sang Oh , Joong-Seok Kim, Phil Hyu Lee.. Effect of Rivastigmine on Behavioral and Psychiatric Symptoms of Parkinson's Disease Dementia J Mov Disord 2015 May;8(2):98-102.
  358. Fasano A, Ricciardi L, Pettorruso M, Bentivoglio AR. Management of punding in Parkinson’s disease: an open-label prospective study. J Neurol. 2011 Apr;258(4):656-60. https://doi.org/10.1007/s00415-010-5817-8.
  359. Cilia R, Siri C, Canesi M, Zecchinelli AL, De Gaspari D, Natuzzi F et al. Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterisation to management and long-term outcome. J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):311-8.
  360. Okai D, Askey-Jones S, Samuel M, et al. Trial of CBT for impulse+ control behaviors affecting Parkinson patients and their caregivers.Neurology 2013;80:792-799].
  361. Lahrmann H., Cortelli P., Hilz M., et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol. 2006; 13(9): 930-936.
  362. Freeman R., Wieling W., Axelrod F.B., et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci 2011; 161(1–2):46–48.
  363. Gibbons C.H., Schmidt P., Biaggioni I., et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017; 264(8):1567-1582.
  364. Centi J., Freeman R., Gibbons C.H., et al. Effects of orthostatic hypotension on cognition in Parkinson disease. Neurology. 2017; 88(1):17-24.
  365. Ferreira J., Katzenschlager R., Bloem B., et al. Summary of the recommendations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease European Journal of Neurology 2013, 20: 5–15.
  366. Grosset D., Grosset K., Okun M., et al. Parkinson’s Disease. Manson Publishing Ltd. 2009. P.176.
  367. Puvi-Rajasingham S., Mathias C.J. Effect of meal size on post-prandial blood pressure and on postural hypotension in primary autonomic failure. Clin Auton Res. J Clin Auton Res Soc. 1996; 6(2):111–114.
  368. Puisieux F., Boumbar Y., Bulckaen H., et al. Intraindividual variability in orthostatic blood pressure changes among older adults: the influence of meals. J Am Geriatr Soc. 1999; 47(11):1332–1336.
  369. Mathias C.J., Fosbraey P., Da Costa D.F., et al. The effect of desmopressin on nocturnal polyuria, overnight weight loss, and morning postural hypotension in patients with autonomic failure. British Medical Journal (Clinical Research Ed.) 1986; 293: 353– 354.
  370. Ten Harkel A.D., Van Lieshout J.J., Wieling W. Effects of leg muscle pumping and tensing on orthostatic arterial pressure: a study in normal subjects and patients with autonomic failure.Clinical Science (London). 1994; 87: 553– 558.
  371. Van Dijk N., De Bruin I.G.J.M., Gisolf J., et al. Hemodynamic effects of legcrossing and skeletal muscle tensing during free standing in patients with vasovagal syncope. Journal of Applied Physiology. 2005; 98: 584– 590.
  372. Harms M.P., Wieling W., Colier W.N., et al. Central and cerebrovascular effects of leg crossing in humans with sympathetic failure. Clin Sci (Lond). 2010;118(9):573-581.
  373. Van Lieshout J.J., Ten Harkel A.D., et al. Fludrocortisone and sleeping in the head‐up position limit the postural decrease in cardiac output in autonomic failure. Clinical Autonomic Research. 2000; 10: 35– 42.
  374. Wieling W., van Lieshout J.J., van Leeuwen A.M. Physical manoeuvres that reduce postural hypotension in autonomic failure. J Clin Auton Res Soc. 1993; 3(1):57–65.
  375. Denq J.C., Opfer‐Gehrking T.L., Giuliani M., et al. Efficacy of compression of different capacitance beds in the amelioration of orthostatic hypotension. Clinical Autonomic Research. 1997; 7: 321– 326.
  376. Smeenk H.E., Koster M.J., Faaij R.A., et al. Compression therapy in patients with orthostatic hypotension: a systematic review. Neth J Med. 2014;72(2):80-85.
  377. Smith G.D., Mathias C.J. Postural hypotension enhanced by exercise in patients with chronic autonomic failure. QJM 1995;88(4):251–256
  378. Mathias C.J., Young T.M. Water drinking in the management of orthostatic intolerance due to orthostatic hypotension, vasovagal syncope and the postural tachycardia syndrome. European Journal of Neurology. 2004; 11: 613–619
  379. Mtinangi B.L., Hainsworth R. Early effects of oral salt on plasma volume, orthostatic tolerance, and baroreceptor sensitivity in patients with syncope. J Clin Auton Res Soc. 1998; 8(4):231–235
  380. Kerstens M.N., Kobold A.C., Volmer M., et al. Reference Values for Aldosterone–Renin Ratios in Normotensive Individuals and Effect of Changes in Dietary Sodium Consumption. Clin Chem 2011; 57(11):1607–1611.
  381. Jordan J., Shannon J.R., Black B.K., et al. The pressor response to water drinking in humans: a sympathetic reflex? Circulation 2000; 101(5):504–509
  382. Young T.M., Mathias C.J. The effects of water ingestion on orthostatic hypotension in two groups of chronic autonomic failure: multiple system atrophy and pure autonomic failure. J Neurol Neurosurg Psychiatry. 2004; 75(12):1737-41.
  383. May M., Jordan J. The osmopressor response to water drinking. Am J Physiol Regul Integr Comp Physiol. 2011; 300(1):R40-6.
  384. Claydon V.E., Schroeder C., Norcliffe L.J., et al. Water drinking improves orthostatic tolerance in patients with posturally related syncope. Clin Sci (Lond). 2006; 110(3):343-52.
  385. Hoehn M.M. Levodopa‐induced postural hypotension. Treatment with fludrocortisone. Arch Neurol. 1975; 32: 50– 51.
  386. Schoffer K.L., Henderson R.D., O'Maley K., et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord. 2007; 22: 1543–1549.
  387. Schoffer K.L., Henderson R.D., O'Maley K., et al. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov. Disord. 2007; 22: 1543–1549.
  388. Sigurdardottir G.R., Nilsson C., Odin P., et al. Cardiovascular effects of domperidone in patients with Parkinson's disease treated with apomorphine. Acta neurologica Scandinavica. 2001;104(2):92–96.
  389. Proulx M., de Courval F.P., Wiseman M., et al. Salivary production in Parkinson’s Disease. Movement Disorders. 2005; 20: 204-207
  390. van Wamelen D.J., Leta V., Johnson J., et al. Drooling in Parkinson's Disease: Prevalence and Progression from the Non-motor International Longitudinal Study. Dysphagia. 2020; 35(6):955-961.
  391. Nobrega A.C., Rodrigues B., Torres A.C., et al. Is drooling secondary to a swallowing disorder in patients with Parkinson’s disease? Parkinsonism Relat Disord. 2008; 14(3): 243-245.
  392. Chen Z., Li G., Liu J. Autonomic dysfunction in Parkinson's disease: Implications for pathophysiology, diagnosis, and treatment. Neurobiol Dis. 2020; 134:104700.
  393. South A. R., Somers S. M., Jog M. S. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology. 2010; 15:1198–1202.
  394. Zhang Z., Chen S.D. Autonomic Dysfunctions in Parkinson’s Disease: Prevalence, Clinical Characteristics, Potential Diagnostic Markers, and Treatment. Hindawi Parkinson’s Disease. 2020; ID 8740732, 10 p. https://doi.org/10.1155/2020/8740732.
  395. Davydov L., Botts S.R. Clozapine-induced hypersalivation Ann Pharmacother. 2000; 34: 662-665.
  396. Chatelut E., Rispail Y., Berlan M., et al. Yohimbine increases human salivary secretion Br J Clin Pharmacol. 1989; 28:366-368.
  397. Srivanitchapoom P., Pandey S., Hallett M. Drooling in Parkinson's disease: A review. Parkinsonism & Related Disorders. 2014; 20(Issue 11):1109-1118.
  398. Egevad, G., Petkova, V.Y., et al. Sialorrhea in patients with Parkinson's disease: safety and administration of botulinum neurotoxin. J. Parkinsons Dis. 2014; 4, 321–326.
  399. Ruiz-Roca J.A., Pons-Fuster E., Lopez-Jornet P. Effectiveness of the Botulinum Toxin for Treating Sialorrhea in Patients with Parkinson's Disease: A Systematic Review. J Clin Med. 2019;8(3):317.
  400. Sridharan K., Sivaramakrishnan G. Pharmacological interventions for treating sialorrhea associated with neurological disorders: A mixed treatment network metaanalysis of randomized controlled trials. J. Clin. Neurosci. 2018;51:12–17.
  401. Chou K. L., Evatt M., Hinson V., et al. Sialorrhea in Parkinson’s disease: a review. Movement Disorders. 2007; 16: 2306–2313.
  402. Camilleri M., Parkman H.P., Shafi M.A., et al. American College of G. Clinical guideline: management of gastroparesis. Am J Gastroenterol.2013; 108(1):18–37.
  403. Palma J.A., Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies.Mov Disord. 2018;33(3):372-390.
  404. Soykan I., Sarosiek I., Shifflett J., et al. Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 1997; 12(6): 952–957.
  405. Agid Y., Pollak P., Bonnet A.M., et al. Bromocriptine associated with a peripheral dopamine blocking agent in treatment of Parkinson's disease. Lancet. 1979; 1:570–572.
  406. Magnifico F., Pierangeli G., Barletta G., et al. The cardiovascular effects of metoclopramide in multiple system atrophy and pure autonomic failure. Clinical autonomic research: official journal of the Clinical Autonomic Research Society.2001; 11(3):163–168.
  407. Ashraf W., Pfeiffer R.F., Park F., et al. Constipation in Parkinson's disease: objective assessment and response to psyllium. Mov Disord 1997; 12: 946– 951.
  408. Perez-Lloret S., Rey M.V., Pavy-Le Traon A., et al. Emerging drugs for autonomic dysfunction in Parkinson's disease. Expert Opin Emerg Drugs. 2013; 18(1):39-53.
  409. Barichella M., Pacchetti C., Bolliri C., et al. Probiotics and prebiotic fiber for constipation associated with Parkinson disease: An RCT.Neurology. 2016; 87(12):1274–1280
  410. Zangaglia R., Martignoni E., Glorioso M., et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo‐controlled study. Mov Disord. 2007; 22: 1239– 1244.
  411. Ondo W.G., Kenney C., Sullivan K., et al. Placebo-controlled trial of lubiprostone for constipation associated with Parkinson disease. Neurology. 2012;78(21):1650–1654.
  412. Poirier A.A., Aubé B., Côté M., et al. Gastrointestinal Dysfunctions in Parkinson’s Disease: Symptoms and Treatments. Parkinson’s Disease. 2016; ID 6762528, 23 p.
  413. Batla A., Tayim N., Pakzad M., et al. Treatment Options for Urogenital Dysfunction in Parkinson's Disease. Curr Treat Options Neurol. 2016; 18(10):45.
  414. Griffiths D.J., McCracken P.N., Harrison G.M., et al. Relationship of fluid intake to voluntary micturition and urinary incontinence in geriatric patients. Neurourol Urodyn.1993;12(1):1–7.
  415. Aranda B., Cramer P. Effects of apomorphine and L‐dopa on the parkinsonian bladder.Neurourol Urodyn. 1993; 12: 203– 209.
  416. Benson G.S., Raezer D.M., Anderson J.R., et al. Effect of levodopa on urinary bladder. Urology 1976; 7: 24– 28.
  417. Winge K., Werdelin L.M., Nielsen K.K., et al. Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn. 2004; 23: 689– 696.
  418. Sakakibara, R., Panicker, J., Finazzi-Agro, E., et al. Parkinson's Disease Subcomittee, T.N.P.C.i.T.I.C.S,. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol. Urodynam. 2016: 35, 551–563.
  419. Christmas T.J., Kempster P.A., Chapple C.R., et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988; 2:1451– 1453.
  420. Brusa L., Petta F., Farullo G., et al. Rotigotine Effects on Bladder Function in Patients with Parkinson's Disease. Mov Disord Clin Pract. 2017; 4(4):586-589.
  421. Suchowersky O., Furtado S., Rohs G. Beneficial effect of intranasal desmopressin for nocturnal polyuria in Parkinson's disease. Mov Disord 1995; 10:337–340.
  422. Sakakibara R., Matsuda S., Uchiyama T., et al. The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res. 2003;13:106–108.
  423. Mattiasson A., Abrams P., Van Kerrebroeck P., et al. Efficacy of desmopressin in the treatment of nocturia: a double‐blind placebo‐controlled study in men. BJU Int. 2002; 89:855–862.
  424. Batla A., Phé V., De Min L., et al. Nocturia in Parkinson's Disease: Why Does It Occur and How to Manage? Mov Disord Clin Pract. 2016;3(5):443-451.
  425. Reynard J.M., Cannon A., Yang Q., et al. A novel therapy for nocturnal polyuria: a double‐blind randomized trial of frusemide against placebo. Br J Urol 1998; 81:215–218.
  426. Zesiewicz, T.A., Evatt, M., Vaughan, C.P., et al. Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease. Parkinsonism Relat. Disord. 2015; 21: 514–520.
  427. Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Int Med. 2015; 175(3):401–407.
  428. Peyronnet, B., Vurture, G., Palma, J.A., et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort. Parkinsonism Relat. Disord. 2018; 57: 22–26.
  429. Wang J., Zhou Z., Cui Y., et al. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Neurourol Urodyn. 2019;38(1):22-30.
  430. Giannantoni A., Rossi A., Mearini E., et al. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009; 182: 1453– 1457.
  431. Giannantoni A., Conte A., Proietti S., et al. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder. J Urol. 2011; 186(3):960-4.
  432. Kulaksizoglu H., Parman, Y. Use of botulinim toxin-A for the treatment of overactive bladder symptoms in patients with Parkinsons's disease. Parkinsonism Relat. Disord. 2010; 16: 531–534.
  433. Finazzi‐Agro E., Peppe A., D'Amico A., et al. Effects of subthalamic nucleus stimulation on urodynamic findings in patients with Parkinson's disease. J Urol. 2003; 169: 1388– 1391.
  434. Seif C., Herzog J., van der Horst C., et al. Effect of subthalamic deep brain stimulation on the function of the urinary bladder. Ann Neurol. 2004; 55: 118– 120.
  435. Kabay S.C., Kabay S., Yucel M., et al. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson’s disease. Neurourol Urodyn. 2009;28(1):62–67.
  436. Mobley D.F., Khera M., Baum N. Recent advances in the treatment of erectile dysfunction. Postgrad Med J. 2017; 93(1105):679–685.
  437. Hussain I.F., Brady C.M., Swinn M.J., et al. Treatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson's disease or multiple system atrophy with observations on orthostatic hypotension. J Neurol Neurosurg Psychiatry. 2001; 71: 371– 374.
  438. Zesiewicz T. A., Helal M., Hauser R.A. Sildenafil citrate (Viagra) for the treatment of erectile dysfunction in men with Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2000; 15(2):305–308.
  439. Raffaele R., Vecchio I., Giammusso B., et al. Efficacy and safety of fixed-dose oral sildenafil in the treatment of sexual dysfunction in depressed patients with idiopathic Parkinson's disease. Eur Urol 2002; № 41(4): 382–386.
  440. Friedman JH. Viewpoint: Challenges in our understanding of neuroleptic induced parkinsonism. Park Relat Disord; 2014;20:1325–8.
  441. Susatia F, Fernandez H. Drug-induced parkinsonism. Curr Treat Options Neurol. 2009;11:162–9.
  442. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract. 2007;13(1):13–24.
  443. Satterthwaite TD, Wolf DH, Rosenheck RA, Gur RE, Caroff SN. A meta-analysis of the risk of acute extrapyramidal symptoms with intramuscular antipsychotics for the treatment of agitation. J Clin Psychiatry. 2008;69(12):1869–79.
  444. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry. 1988;51:850–4
  445. Marjama-Lyons J., Koller W. Tremor-predominant Parkinson’s disease //Drugs & aging. – 2000. – Т. 16. – №. 4. C. 273-278
  446. Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, et al. Clinical characteristics of neuroleptic-induced parkinsonism. J Neural Transm. 2001;108(11):1299–308
  447. Bohlega SA, Al-Foghom NB. Drug-induced Parkinson’s disease. Neurosciences. 2013;18(3):215–21.
  448. Hardie RJ, Lees AJ. Neuroleptic-induced Parkinson’s syndrome: clinical features and results of treatment with levodopa. J Neurol Neurosurg Psychiatry 1988;51:850–4.
  449. Wardlaw J., Debette S., Jokinen H., et al. ESO Guideline on covert cerebral small vessel disease. European Stroke Journal, First Published May 11, 2021,https://doi.org/10.1177/23969873211012132
  450. Spence JD. Management of asymptomatic carotid stenosis. Ann Transl Med 2020;8(19):1262. doi: 10.21037/atm-20-975
  451. Vizcarra, J.A., Lang, A.E., Sethi, K.D., Espay, A.J., 2015. Vascular parkinsonism: Deconstructing a syndrome. Movement Disorders 30 (7), 886–894.ъ
  452. Zijlmans, J. C. M., Katzenschlager, R., Daniel, S. E., Lees, A. J. L. 2004. The L- dopa response in vascular parkinsonism. Journal of Neurology, Neurosurgery & Psychiatry, 75(4), 545-547.
  453. Knight R, Khondoker M, Magill N, Stewart R, Landau S. A Systematic Review and Meta-Analysis of the Effectiveness of Acetylcholinesterase Inhibitors and Memantine in Treating the Cognitive Symptoms of Dementia. Dement Geriatr Cogn Disord. 2018;45(3-4):131- 151. doi: 10.1159/000486546. Epub 2018 May 7. PMID: 29734182.
  454. Moretti DV. Available and future treatments for atypical parkinsonism. A systematic review. CNS Neurosci Ther. 2019 Feb;25(2):159-174. doi: 10.1111/cns.13068. Epub 2018 Oct 7. PMID: 30294976; PMCID: PMC6488913.
  455. Stamelou M, Höglinger G. A Review of Treatment Options for Progressive Supranuclear Palsy. CNS Drugs. 2016 Jul;30(7):629-36. doi: 10.1007/s40263-016-0347-2. PMID: 27222018.
  456. Kompoliti K. et al. Pharmacological therapy in progressive supranuclear palsy//Archives of neurology. – 1998. – Т. 55. – №. 8. C. 1099-1102.
  457. Nuebling G, Hensler M, Paul S, Zwergal A, Crispin A, Lorenzl S. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy. J Neurol. 2016 Aug;263(8):1565-74.
  458. Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O; Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2015 Feb;14(2):145-52.
  459. Moretti DV, Binetti G, Zanetti O, Frisoni GB. Non-ergot dopamine agonist rotigotine as a promising therapeutic tool in atypical parkinsonism syndromes: a 24 months pilot observational open-label study. Neuropharmacology. 2014 Oct;85:284-9.
  460. Moretti DV, Binetti G, Zanetti O, Frisoni GB. Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy. Neuropsychiatr Dis Treat. 2014 Jun 5;10:1003-9.
  461. Litvan I, Phipps M, Pharr VL, Hallett M, Grafman J, Salazar A. Randomized placebo-controlled trial of donepezil in patients with progressive supranuclear palsy. Neurology. 2001 Aug 14;57(3):467-73.
  462. Fabbrini G, Barbanti P, Bonifati V, Colosimo C, Gasparini M, Vanacore N, Meco G. Donepezil in the treatment of progressive supranuclear palsy. Acta Neurol Scand. 2001 Feb;103(2):123-5.
  463. Kompoliti K, Goetz CG, Boeve BF, Maraganore DM, Ahlskog JE, Marsden CD, Bhatia KP, Greene PE, Przedborski S, Seal EC, Burns RS, Hauser RA, Gauger LL, Factor SA, Molho ES, Riley DE. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol. 1998 Jul;55(7):957-61.
  464. Ling H, O'Sullivan SS, Holton JL, Revesz T, Massey LA, Williams DR, Paviour DC, Lees AJ. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010 Jul;133(Pt 7):2045-57.
  465. Marsili L, Suppa A, Berardelli A, Colosimo C. Therapeutic interventions in parkinsonism: Corticobasal degeneration. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S96- 100.
  466. Cordivari C, Misra VP, Catania S, Lees AJ. Treatment of dystonic clenched fist with botulinum toxin. Mov Disord. 2001 Sep;16(5):907-13.
  467. Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco- economic value. J Neurol. 2012 Dec;259(12):2519-26.
  468. Bianchi M, Cosseddu M, Cotelli M, Manenti R, Brambilla M, Rizzetti MC, Padovani A, Borroni B. Left parietal cortex transcranial direct current stimulation enhances gesture processing in corticobasal syndrome. Eur J Neurol. 2015 Sep;22(9):1317-22. doi: 10.1111/ene.12748. Epub 2015 Jun 13.
  469. Manenti R, Bianchi M, Cosseddu M, Brambilla M, Rizzetti C, Padovani A, Borroni B, Cotelli M. Anodal transcranial direct current stimulation of parietal cortex enhances action naming in Corticobasal Syndrome. Front Aging Neurosci. 2015 Apr 14;7:49.
  470. Civardi C, Pisano F, Delconte C, Collini A, Monaco F. Effects of slow repetitive transcranial magnetic stimulation in patients with corticobasal syndrome. Neurol Sci. 2015 Jun;36(6):1007-9.
  471. Rajput AH, Rozdilsky B, Rajput A, Ang L. Levodopa efficacy and pathological basis of Parkinson syndrome. Clin Neuropharmacol. 1990 Dec;13(6):553-8.
  472. Parati EA, Fetoni V, Geminiani GC, Soliveri P, Giovannini P, Testa D, Genitrini S, Caraceni T, Girotti F. Response to L-DOPA in multiple system atrophy. Clin Neuropharmacol. 1993 Apr;16(2):139-44.
  473. Wenning GK, Ben Shlomo Y, Magalhães M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. 1994 Aug;117 ( Pt 4):835-45.
  474. Flabeau O, Meissner WG, Tison F. Multiple system atrophy: current and future approaches to management. Ther Adv Neurol Disord. 2010 Jul;3(4):249-63.
  475. Fanciulli A, Stankovic I, Krismer F, Seppi K, Levin J, Wenning GK. Multiple system atrophy. Int Rev Neurobiol. 2019;149:137-192.
  476. Wenning GK; Working Group on Atypical Parkinsonism of the Austrian Parkinson's Society. Placebo-controlled trial of amantadine in multiple-system atrophy. Clin Neuropharmacol. 2005 Sep-Oct;28(5):225-7.
  477. Rajrut AH, Uitti RJ, Fenton ME, George D. Amantadine effectiveness in multiple system atrophy and progressive supranuclear palsy. Parkinsonism Relat Disord 1997;3 211-214.
  478. Friess E, Kuempfel T, Modell S, Winkelmann J, Holsboer F, Ising M, Trenkwalder C. Paroxetine treatment improves motor symptoms in patients with multiple system atrophy. Parkinsonism Relat Disord. 2006 Oct;12(7):432-7.
  479. Tada M, Kakita A, Toyoshima Y, Onodera O, Ozawa T, Morita T, Nishizawa M, Takahashi H. Depletion of medullary serotonergic neurons in patients with multiple system atrophy who succumbed to sudden death. Brain. 2009 Jul;132(Pt 7):1810-9.
  480. Benarroch EE. Brainstem respiratory control: substrates of respiratory failure of multiple system atrophy. Mov Disord. 2007 Jan 15;22(2):155-61.
  481. Zhang LY, Cao B, Zou YT, Wei QQ, Ou RW, Zhao B, Wu Y, Shang HF. Depression and anxiety in multiple system atrophy. Acta Neurol Scand. 2018 Jan;137(1):33-37.
  482. Jain S, Dawson J, Quinn NP, Playford ED. Occupational therapy in multiple system atrophy: a pilot randomized controlled trial. Mov Disord 2004;19:1360-1364.
  483. Silva-Batista C, Kanegusuku H, Roschel H, Souza EO, Cunha TF, Laurentino GC, Manoel N Jr, De Mello MT, Piemonte ME, Brum PC, Forjaz CL, Tricoli V, Ugrinowitsch C. Resistance training with instability in multiple system atrophy: a case report. J Sports Sci Med. 2014 Sep 1;13(3):597-603.
  484. Hohler AD, Tsao JM, Katz DI, Dipiero TJ, Hehl CL, Leonard A, Allen V, Gardner M, Phenix H, Saint-Hilaire M, Ellis T. Effectiveness of an inpatient movement disorders program for patients with atypical parkinsonism. Parkinsons Dis. 2012;2012:871974.
  485. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med 1993;95:38-48.
  486. Ten Harkel AD, Van Lieshout JJ, Wieling W. Treatment of ortho- static hypotension with sleeping in the head-up tilt position, alone and in combination with fludrocortisone. J Intern Med 1992;232139-145.
  487. Schoffer KL, Henderson RD, O'Maley K, O’Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-1549.
  488. Brooks DJ, Redmond S, Mathias CJ, Bannister R, Symon L. The effect of orthostatic hypotension on cerebral blood flow and mid- dle cerebral artery velocity in autonomic failure, with observations on the action of ephedrine. J Neurol Neurosurg Psychiatry 1989;52 962-966.
  489. Peyronnet B, Vurture G, Palma JA, et al. Mirabegron in patients with Parkinson disease and overactive bladder symptoms: a retrospective cohort. Parkinsonism Relat Disord 2018;57:22-26.
  490. Gubbiotti M, Conte A, Di Stasi SM, Tambasco N, Giannantoni A. Feasibility of mirabegron in the treatment of overactive bladder in patients affected by Parkinson’s disease: a pilot study. Ther Adv Neurol Disord 2019;12:1756286419843458.
  491. Athanasiou S, Pitsouni E, Grigoriadis T, Zacharakis D, Salvatore S, Serati M. Mirabegron in female patients with overactive bladder syndrome: what’s new? A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020;251:73-82.
  492. Giannantoni A, Rossi A, Mearini E, Del Zingaro M, Porena M, Berardelli A. Botulinum toxin A for overactive bladder and detrusor muscle overactivity in patients with Parkinson's disease and multiple system atrophy. J Urol 2009;182 1453-1457.
  493. Knuepfer S, Juenemann KP. Experience with botulinum toxin type A in the treatment of neurogenic detrusor overactivity in clinical practice. Ther Adv Urol 2014;6:34-42.
  494. Papatsoris AG, Papapetropoulos S, Singer C, Deliveliotis C. Urinary and erectile dysfunction in multiple system atrophy (MSA). Neurourol Urodyn. 2008;27(1):22-7.
  495. Moussa M, Papatsoris A, Chakra MA, Fares Y, Dellis A. Lower urinary tract dysfunction in common neurological diseases. Turk J Urol. 2020 Nov;46(Supp. 1):S70-S78.
  496. Chou KL, Forman MS, Trojanowski JQ, Hurtig HI, Baltuch GH. Subthalamic nucleus deep brain stimulation in a patient with levodopa-responsive multiple system atrophy. Case report. J Neurosurg 2004;100 553-556.
  497. Lezcano E, Gomez-Esteban JC, Zarranz JJ, et al. Parkinson's disease-like presentation of multiple system atrophy with poor response to STN stimulation: a clinicopathological case report. Mov Disord 2004;19 973-977.
  498. Meissner WG, Laurencin C, Tranchant C, et al. Outcome of deep brain stimulation in slowly progressive multiple system atrophy: a clinico-pathological series and review of the literature. Parkinsonism Relat Disord 2016;24:69-75.
  499. Arnold AC, Raj SR. Orthostatic Hypotension: A Practical Approach to Investigation and Management. Can J Cardiol. 2017 Dec; 33(12):1725-1728
  500. Palma J.A., Kaufmann H. Treatment of autonomic dysfunction in Parkinson disease and other synucleinopathies. Mov Disord. 2018 Mar; 33(3):372-390
  501. Gibbons CH, Schmidt P, Biaggioni I, Frazier-Mills C, Freeman R, Isaacson S, Karabin B, Kuritzky L, Lew M, Low P, Mehdirad A, Raj SR, Vernino S, Kaufmann H. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol. 2017 Aug; 264(8):1567- 1582
  502. Bassani T, Bari V, Marchi A, Tassin S, Dalla Vecchia L, Canesi M, Barbic F, Furlan R, Porta A. Model-free causality analysis of cardiovascular variability detects the amelioration of autonomic control in Parkinson's disease patients undergoing mechanical stimulation. Physiol Meas. 2014 Jul; 35(7):1397-408.
  503. Barbic F, Galli M, Dalla Vecchia L, Canesi M, Cimolin V, Porta A, Bari V, Cerri G, Dipaola F, Bassani T, Cozzolino D, Pezzoli G, Furlan R. Effects of mechanical stimulation of the feet on gait and cardiovascular autonomic control in Parkinson's disease. J Appl Physiol (1985). 2014 Mar 1; 116(5):495-503.
  504. Lucetti, Claudio et al. Levodopa response in dementia with lewy bodies: A 1-year follow-up study. Parkinsonism & Related Disorders, Vol 16, Issue 8, 522 – 52
  505. Molloy S, McKeith IG, O'Brien JT, Burn DJ. The role of levodopa in the management of dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2005;76(9):1200– 1203.
  506. Goldman J. G. et al. Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies //Movement disorders: official journal of the Movement Disorder Society. – 2008. – Т. 23. – №. 15. C. 2248-2250
  507. Molloy, S., Minett, T., O'Brien, J.T., McKeith, I.G. and Burn, D.J. (2009), Levodopa use and sleep in patients with dementia with Lewy bodies. Mov. Disord., 24: 609-612.
  508. Fujishiro, H., Kasanuki, K. and Nakamura, S. (2013), L‐dopa and mood fluctuation in DLB. Psychogeriatrics, 13: 250-253. doi:10.1111/psyg.12025
  509. Molloy SA, Rowan EN, O'Brien JT, McKeith IG, Wesnes K, Burn DJ. Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2006;77(12):1323–1328.
  510. Stinton C. et al. Pharmacological management of Lewy body dementia: a systematic review and meta-analysis //American Journal of Psychiatry. – 2015. – Т. 172. – №. 8. C. 731-742
  511. Wang H, Yu J, Tang S, et al. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis. Journal of Neurology, Neurosurgery & Psychiatry 2015;86:135-143.
  512. Meng YH, Wang PP, Song YX, Wang JH. Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis. Exp Ther Med. 2019;17(3):1611–1624.
  513. Rolinski M, Fox C, Maidment I, McShane R. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease. Cochrane Database of Systematic Reviews 2012, Issue 3.
  514. Wild R, Pettit TACL, Burns A. Cholinesterase inhibitors for dementia with Lewy bodies. Cochrane Database of Systematic Reviews 2003, Issue 3.
  515. Dou KX, Tan MS, Tan CC, et al. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials. Alzheimers Res Ther. 2018;10(1):126.
  516. Brennan L., Pantelyat A., Duda J.E. et al. Memantine and Cognition in Parkinson's Disease Dementia/Dementia With Lewy Bodies: A Meta-Analysis. Mov Disord Clin Pract. 2015;3(2):161–167.
  517. Fischer C., Bozanovic R., Atkins J., Rourke S. Treatment of Delusions in Dementia with Lewy Bodies – Response to Pharmacotherapy. Dement Geriatr Cogn Disord 2007;23:307-311.
  518. Schneider L.S., Dagerman K.S., Insel P. Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia: Meta-analysis of Randomized Placebo-Controlled Trials. JAMA. 2005;294(15):1934–1943.
  519. Yunusa I., Alsumali A, Garba AE, Regestein QR, Eguale T. Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis. JAMA Netw Open. 2019;2(3):e190828. Published 2019 Mar 1.
  520. Ma Huia; Huang Yinglina; Cong Zhengtua, Wang, Yuana, Jiang, Wenhaid, Gao Shuhed, Zhun Ganga The Efficacy and Safety of Atypical Antipsychotics for the Treatment of Dementia: A Meta-Analysis of Randomized Placebo-Controlled Trials
  521. Aarsland D., Perry R., Larsen J.P., McKeith I. G., et al. Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. J Clin Psychiatry 2005;66(5):633-637
  522. Akiko Kobayashi, Chiaki Kawanishi, Takehiko Matsumura, Daiji Kato, Ryoko Furukawa, Ikuko Kishida, Yoshio Hirayasu. Quetiapine-induced neuroleptic malignant syndrome in dementia with Lewy bodies: A case report. Progress in Neuro- Psychopharmacology and Biological Psychiatry, Volume 30, Issue 6, 2006, Pages 1170-1172.
  523. Piggott M. A. et al. Nigrostriatal dopaminergic activities in dementia with lewy bodies in relation to neuroleptic sensitivity: comparisons with parkinson’s disease. Biological Psychiatry, Volume 44, Issue 8, 765 – 774
  524. Sechi G., Agnetti V., Masuri R., Deiana A. G. et al. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies, Progress in Neuro- Psychopharmacology and Biological Psychiatry, Volume 24, Issue 6, 2000, Pages 1043-1051.
  525. Hubert H. Fernandez, Martha E. Trieschmann, Monica A. Burke, and Joseph H. Friedman Quetiapine for Psychosis in Parkinson's Disease Versus Dementia With Lewy Bodies. J Clin Psychiatry 2002;63(6):513-515.
  526. Kurlan R. et al. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism //Neurology. – 2007. – Т. 68. – №. 17. C. 1356-1363.
  527. Bhamra M, Rajkumar AP, Ffytche DH, et al. Successful management of persistent distressing neuropsychiatric symptoms by clozapine in a patient suffering from dementia with Lewy bodies. Case Reports 2018;2018:bcr-2018-224710.
  528. Hitoshi Takahashi, Keizo Yoshida, Takio Sugita, Hisashi Higuchi, Tetsuo Shimizu, Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: A case series, Progress in Neuro-Psychopharmacology and Biological Psychiatry, Volume 27, Issue 3, 2003, Pages 549-553,
  529. Andrius Baskys, MD, PhD. Lewy Body Dementia: The Litmus Test for Neuroleptic Sensitivity and Extrapyramidal Symptoms. J Clin Psychiatry 2004;65(suppl 11):16- 22
  530. Shibao CA, Kaufmann H. Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease. CNS Drugs. 2017 Nov; 31(11):975-989
  531. Taylor J.P, McKeith I.G. New evidence on the management of Lewy body dementia. Lancet Neurol. 2020;19(2): с.157-169
  532. Comella CL, Nardine TM, Diederich NJ, Stebbins G.T. Sleep-related violence, injury, and REM sleep behavior disorder in Parkinson's disease. Neurology. 1998 Aug; 51(2):526-9.
  533. Aurora RN, Zak RS, Maganti RK, Auerbach SH, Casey KR, Chowdhuri S, Karippot A, Ramar K, Kristo DA, Morgenthaler TI, Standards of Practice Committee., American Academy of Sleep Medicine. Best practice guide for the treatment of REM sleep behavior disorder (RBD). J Clin Sleep Med. 2010 Feb 15; 6(1):85-95.
  534. Schenck CH, Montplaisir JY, Frauscher B et al. Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med. 2013 Aug; 14(8):795-806.
  535. Fantini ML, Gagnon JF, Filipini D, Montplaisir J. The effects of pramipexole in REM sleep behavior disorder. Neurology. 2003 Nov 25; 61(10):1418-20.
  536. Ringman JM, Simmons J.H. Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology. 2000 Sep 26; 55(6):870-1.
  537. Massironi G1, Galluzzi S, Frisoni G.B. Drug treatment of REM sleep behavior disorders in dementia with Lewy bodies. Int Psychogeriatr. 2003 Dec;15(4):377-83
  538. Larsson V., Aarsland D., Ballard C., Minthon L. and Londos E. (2010), The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriat. Psychiatry, 25: 1030-1038.
  539. Chen H., Zhang S., Hernan M., et al. Weight loss in Parkinson’s disease. Ann Neurol. 2003;53:676-9.
  540. Uc E., Struck L., Rodnitzky R., et al. Predictors of weight loss in Parkinson’s disease. Mov Disord. 2006;21:930-6.
  541. Markus H., Cox M., Tomkins A. Raised resting energy expenditure in Parkinson's disease and its relationship to muscle rigidity. Clin Sci (Lond).1992;83:199-204
  542. Barclay L., High-Fiber D. Low-Saturated-Fat Diet May Protect Against Parkinson's Disease. Am J Clin Nutr. 2007;86:1486-1494.;
  543. Alcalay R. N., Gu Y., Mejia-Santana H., Cote L., Marder K. S., Scarmeas N. The association between Mediterranean diet adherence and Parkinson’s disease. Movement Disorders. 2012;27:771–774.
  544. Gao X., Cassidy A., Schwarzschild M.A. et al. Habitual intake of dietary flavonoids and risk of Parkinson’s disease. Neurology. 2012; 78. (15):1138-45.
  545. Powers K., Smith-Weller T., G. M. Franklin, et al. Dietary fats, cholesterol and iron as risk factors for Parkinson’s disease. Parkinsonism and Related Disorders 2009;15:47-52.
  546. Anderson C, Checkoway H, Franklin GM, et al. Dietary factors in Parkinson's disease: the role of food groups and specific foods. Mov Disord. 1999;14(1):21-7.
  547. Barclay L., High-Fiber D. Low-Saturated-Fat Diet May Protect Against Parkinson's Disease. Am J Clin Nutr. 2007;86:1486-1494.
  548. Logroscino G, Marder K, Cote L, et al. Dietary lipids and antioxidants in Parkinson's disease: a population-based, case-control study. Ann Neurol. 1996;39(1):89-94.
  549. Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell CD, Skeaff CM. Effects of total fat intake on body weight. Cochrane Database Syst Rev. 2015; (8):CD011834.
  550. Hooper L, Abdelhamid A, Bunn D, Brown T, Summerbell CD, Skeaff CM. Effects of total fat intake on body weight. Cochrane Database Syst Rev. 2015; (8):CD011834.
  551. Fats and fatty acids in human nutrition: report of an expert consultation. FAO Food and Nutrition Paper 91. Rome: Food and Agriculture Organization of the United Nations; 2010;
  552. Agim ZS, Cannon JR. Dietary factors in the etiology of Parkinson's disease. Biomed Res Int. 2015;2015:672838.
  553. Wang A, Lin Y, Wu Y, et al. Macronutrients intake and risk of Parkinson's disease: A meta-analysis. Geriatr Gerontol Int. 2015;15(5):606-16
  554. Costantini A, Fancellu R. An open-label pilot study with high-dose thiamine in Parkinson's disease. Neural Regen Res. 2016;11(3):406-7. [PMID:27127471];
  555. Luong KV, Nguyen LT. The beneficial role of thiamine in Parkinson disease. CNS Neurosci Ther. 2013;19(7):461-8. [PMID:23462281];
  556. Suzuki M, Yoshioka M, Hashimoto M, et al. Randomized, double-blind, placebo- controlled trial of vitamin D supplementation in Parkinson disease. Am J Clin Nutr. 2013;97(5):1004-13.
  557. Nutt J.G., Fellman J.H. Pharmacokinetics of levodopa. Clin. Neuropharmacol. 1984; 7: 35-49. Jankovic J. Levodopa strengths and weaknesses. Neurology. 2002; 58: 19-32.;
  558. Pletscher A., DaPrada M. Pharmacotherapy of Parkinson’s disease: research fr om 1960 to 1991. Acta. Neurol. Scand. Suppl. 1993;146: 26-31.;
  559. Yahr M.D., Duvoisin R.C., Schear M.J., Barrett R.E., Hoehn M.M.: Treatment of parkinsonism with levodopa. Arch. Neurol. 1969; 21: 343-354.
  560. Cereda E, Barichella M, Pezzoli G. Controlled-protein dietary regimens for Parkinson's disease. Nutr Neurosci. 2010 Feb;13(1):29-32. doi: 10.1179/147683010X12611460763760. PMID: 20132652
  561. Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008;23:1146– 1153.
  562. Alomar S, King NK, Tam J, Bari AA, Hamani C, Lozano AM. Speech and language adverse effects after thalamotomy and deep brain stimulation in patients with movement disorders: A meta-analysis. Mov Disord. 2017 Jan;32(1):53-63. doi: 10.1002/mds.26924. PMID: 28124434.
  563. Bond, Aaron E et al. “Safety and Efficacy of Focused Ultrasound Thalamotomy for Patients With Medication-Refractory, Tremor-Dominant Parkinson Disease: A Randomized Clinical Trial.” JAMA neurology vol. 74,12 (2017): 1412-1418. doi:10.1001/jamaneurol.2017.3098
  564. Esselink RA, de Bie RM, de Haan RJ, et al. Unilateral pallidotomy versus bilateral subthalamic nucleus stimulation in Parkinson’s disease: one year follow-up of a randomised observer-blind multi centre trial. Acta Neurochir (Wien) 2006;148:1247–1255; discussion 1255.
  565. Esselink RA, de Bie RM, de Haan RJ, et al. Long-term superiority of subthalamic nucleus stimulation over pallidotomy in Parkinson disease. Neurology 2009;73:151–153.
  566. Vitek JL, Bakay RA, Freeman A, et al. Randomized trial of pallidotomy versus medical therapy for Parkinson’s disease. Ann Neurol 2003;53:558–569
  567. Odekerken VJ, Boel JA, Schmand BA et al. . GPi vs STN deep brain stimulation for Parkinson disease. Neurology. 2016;86(8):755-761.
  568. Deep-Brain Stimulation for Parkinson's Disease Study. G Obeso JA, Olanow CW et al. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med. 2001;345(13):956-963.
  569. Minguez-Castellanos A, Escamilla-Sevilla F, Katati MJ et al. . Different patterns of medication change after subthalamic or pallidal stimulation for Parkinson's disease: target related effect or selection bias? J Neurol Neurosurg Psychiatry. 2005;76(1):34-39.
  570. Evidente VG, Premkumar AP, Adler CH, Caviness JN, Driver-Dunckley E, Lyons MK. Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson's disease. Acta Neurol Scand. 2011;124(3):211-214
  571. Rodriguez-Oroz MC, Obeso JA, Lang AE et al. . Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain. 2005;128(10):2240- 2249
  572. Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology. 2001;56(4):548-551
  573. Odekerken VJ, van Laar T, Staal MJ et al. . Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson's disease (NSTAPS study): a randomised controlled trial. Lancet Neurol. 2013;12(1):37-44
  574. Weaver FM, Follett KA, Stern M et al. . Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology. 2012;79(1):55-65.
  575. Krause M, Fogel W, Heck A et al. . Deep brain stimulation for the treatment of Parkinson's disease: subthalamic nucleus versus globus pallidus internus. J Neurol Neurosurg Psychiatry. 2001;70(4):464-470.
  576. Volkmann J, Albanese A, Kulisevsky J et al. . Long-term effects of pallidal or subthalamic deep brain stimulation on quality of life in Parkinson's disease. Mov Disord. 2009;24(8):1154-1161.
  577. Zhang J, Li J, Chen F, Liu X, Jiang C, Hu X, Ma L, Xu Z. STN versus GPi deep brain stimulation for dyskinesia improvement in advanced Parkinson's disease: A meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2021 Feb;201:106450. doi: 10.1016/j.clineuro.2020.106450. Epub 2020 Dec 31. PMID: 33421741.
  578. Wang JW, Zhang YQ, Zhang XH, Wang YP, Li JP, Li YJ. Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta- Analysis of Randomized Controlled Trials. PLoS One. 2016 Jun 1;11(6):e0156721. doi: 10.1371/journal.pone.0156721. PMID: 27248139; PMCID: PMC4889151.
  579. Peng L, Fu J, Ming Y, Zeng S, He H, Chen L. The long-term efficacy of STN vs GPi deep brain stimulation for Parkinson disease: A meta-analysis. Medicine (Baltimore). 2018 Aug;97(35):e12153. doi: 10.1097/MD.0000000000012153. PMID: 30170458; PMCID: PMC6393030.
  580. Parihar R, Alterman R, Papavassiliou E, Tarsy D, Shih LC. Comparison of VIM and STN DBS for Parkinsonian Resting and Postural/Action Tremor. Tremor Other Hyperkinet Mov (N Y). 2015;5:321. Published 2015 Jul 6. doi:10.7916/D81V5D35
  581. Limousin P, Speelman JD, Gielen F, Janssens M. Multicentre European study of thalamic stimulation in parkinsonian and essential tremor. J Neurol Neurosurg Psychiatry. 1999;66(3):289-296. doi:10.1136/jnnp.66.3.289
  582. Charles, P. D., Van Blercom, N., Krack, P., Lee, S. L., Xie, J., Besson, G., et al. (2002). Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 59, 932–934. doi: 10.1212/wnl.59.6.932
  583. Kim HY, Chang WS, Kang DW, Sohn YH, Lee MS, Chang JW. Factors related to outcomes of subthalamic deep brain stimulation in Parkinson's disease. J Korean Neurosurg Soc. 2013;54(2):118-124. doi:10.3340/jkns.2013.54.2.118
  584. Welter, M. L., Houeto, J. L., Tezenas du Montcel, S., Mesnage, V., Bonnet, A. M., Pillon, B., et al. (2002). Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain 125, 575–583. doi: 10.1093/brain/awf050
  585. Piboolnurak, P., Lang, A. E., Lozano, A. M., Miyasaki, J. M., Saint-Cyr, J. A., Poon, Y.-Y. W., et al. (2007). Levodopa response in long-term bilateral subthalamic stimulation for Parkinson’s disease. Mov. Disord. 22, 990–997. doi: 10.1002/mds.2148
  586. Zaidel, A., Bergman, H., Ritov, Y., and Israel, Z. (2010). Levodopa and subthalamic deep brain stimulation responses are not congruent. Mov. Disord. 25, 2379–2386. doi: 10.1002/mds.23294
  587. Lin Z, Zhang X, Wang L, Zhang Y, Zhou H, Sun Q, Sun B, Huang P, Li D. Revisiting the L-Dopa Response as a Predictor of Motor Outcomes After Deep Brain Stimulation in Parkinson's Disease. Front Hum Neurosci. 2021 Feb 4;15:604433. doi: 10.3389/fnhum.2021.604433. PMID: 33613209; PMCID: PMC7889513.
  588. Kleiner-Fisman, G.; Herzog, J.; Fisman, D.N.; Tamma, F.; Lyons, K.E.; Pahwa, R.; Lang, A.E.; Deuschl, G. Subthalamic nucleus deep brain stimulation: Summary and meta- analysis of outcomes. Mov. Disord. 2006, 21 (Suppl. S14), S290–S304
  589. Defer GL, Widner H, Marié RM, Rémy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT‐PD). 1999;14:572–584 Mov Disord
  590. Bronstein, J.M.; Tagliati, M.; Alterman, R.L.; Lozano, A.M.; Volkmann, J.; Stefani, A.; Horak, F.B.; Okun, M.S.; Foote, K.D.; Krack, P.; et al. Deep brain stimulation for Parkinson disease: An expert consensus and review of key issues. Arch. Neurol. 2011, 68, 165
  591. Artusi CA, Lopiano L, Morgante F. Deep Brain Stimulation Selection Criteria for Parkinson's Disease: Time to Go beyond CAPSIT-PD. J Clin Med. 2020 Dec 4;9(12):3931. doi: 10.3390/jcm9123931. PMID: 33291579; PMCID: PMC7761824.
  592. Saranza G, Lang AE. Levodopa challenge test: indications, protocol, and guide. J Neurol. 2020 Apr 24. doi: 10.1007/s00415-020-09810-7. Epub ahead of print. PMID: 32333167
  593. Fabbri M, Coelho M, Guedes LC et al (2017) Response of nonmotor symptoms to levodopa in late-stage Parkinson’s disease: results of a levodopa challenge test. Parkinsonism Relat Disord 39:37–43
  594. Feng T, Li W, Lu L, Wang Y, Shi W, Zhang J, Wang Y, Chan P. Acute stepwise challenge test with levodopa in treated patients with parkinsonism. Parkinsonism Relat Disord. 2009 Jun;15(5):354-8. doi: 10.1016/j.parkreldis.2008.08.010. Epub 2008 Nov 14. PMID: 19010079.
  595. Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Hälbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltête D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Krüger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-Brittinger C, Deuschl G; EARLYSTIM Study Group. Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med. 2013 Feb 14;368(7):610-22. doi: 10.1056/NEJMoa1205158. PMID: 23406026.
  596. DeLong MR, Huang KT, Gallis J, Lokhnygina Y, Parente B, Hickey P, Turner DA, Lad SP. Effect of advancing age on outcomes of deep brain stimulation for Parkinson disease. JAMA Neurol. 2014 Oct;71(10):1290-5. doi: 10.1001/jamaneurol.2014.1272. PMID: 25155481.
  597. Mansouri A, Taslimi S, Badhiwala JH, Witiw CD, Nassiri F, Odekerken VJJ, De Bie RMA, Kalia SK, Hodaie M, Munhoz RP, Fasano A, Lozano AM. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018 Apr;128(4):1199-1213. doi: 10.3171/2016.11.JNS16715. Epub 2017 Jun 30. PMID: 28665252.
  598. Rothlind JC, York MK, Carlson K, Luo P, Marks WJ Jr, Weaver FM, Stern M, Follett K, Reda D; CSP-468 Study Group. Neuropsychological changes following deep brain stimulation surgery for Parkinson's disease: comparisons of treatment at pallidal and subthalamic targets versus best medical therapy. J Neurol Neurosurg Psychiatry. 2015 Jun;86(6):622-9. doi: 10.1136/jnnp-2014-308119. Epub 2014 Sep 2. PMID: 25185211.
  599. Deuschl G, Herzog J, Kleiner-Fisman G, Kubu C, Lozano AM, Lyons KE, Rodriguez-Oroz MC, Tamma F, Tröster AI, Vitek JL, Volkmann J, Voon V. Deep brain stimulation: postoperative issues. Mov Disord. 2006 Jun;21 Suppl 14:S219-37. doi: 10.1002/mds.20957. PMID: 16810719.
  600. Volkmann J, Moro E, Pahwa R. Basic algorithms for the programming of deep brain stimulation in Parkinson’s disease. Mov Disord 2006;21: S284–9
  601. Volkmann J, Herzog J, Kopper F, Deuschl G. Introduction to the programming of deep brain stimulators. Mov Disord. 2002;17 Suppl 3:S181-7. doi: 10.1002/mds.10162. PMID: 11948775.
  602. Deaths from Neurodegenerative Diseases in England, 2002 to 2008. National end of life care intelligence network. №1, 2010
  603. Gomes B, Calanzani N, Gysels M, Hall S, Higginson I. Heterogeneity and changes in preferences for dying at home: a systematic review. BMC Palliative Care. 2013;12(7):1–13. doi: 10.1186/1472-684X-12-7
  604. Annette Hand, William K. Gray, Lloyd L. Oates, Megan Woolford, Anna Todd, Elizabeth Bale, Catherine Jones, Brian H. Wood, Richard W. Walker. Medication use in people with late stage Parkinson's disease and parkinsonism living at home and in institutional care in north-east England: A balance of symptoms and side-effects? Parkinsonism and Related Disorders 32 (2016) 120-123.doi: 10.1016/j.parkreldis.2016.09.001
  605. Kluger BM, Miyasaki J, Katz M, Galifianakis N, Hall K, Pantilat S, Khan R, Friedman C, Cernik W, Goto Y, Long J, Fairclough D, Sillau S, Kutner JS. Comparison of Integrated Outpatient Palliative Care With Standard Care in Patients With Parkinson Disease and Related Disorders: A Randomized Clinical Trial. JAMA Neurol. 2020 May 1;77(5):551-560. doi: 10.1001/jamaneurol.2019.4992
  606. Holford N, Nutt JG. Disease progression, drug action and Parkinson's disease: why time cannot be ignored. Eur J Clin Pharmacol. 2008 Feb; 64(2):20716. DOI: 10.1007/s00228-007-0427-9
  607. Logemann J.A., Gensler G., Robbins J., et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res. 2008; 51(1):173-183.
  608. Flynn E., Smith C.H., Walsh C.D., et al. Modifying the consistency of food and fluids for swallowing difficulties in dementia. Cochrane Database Syst Rev. 2018;9(9):CD011077.
  609. Newman R., Vilardell N., Clavé P., et al. Effect of Bolus Viscosity on the Safety and Efficacy of Swallowing and the Kinematics of the Swallow Response in Patients with Oropharyngeal Dysphagia: White Paper by the European Society for Swallowing Disorders (ESSD). Dysphagia. 2016;31(2):232-249.
  610. El Sharkawi A., Ramig L., Logemann J.A., et al. Swallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot study. J Neurol Neurosurg Psychiatry. 2002;72(1):31-36.
  611. Miles A., Jardine M., Johnston F., et al. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study. J Neurol Sci. 2017; 383:180-187.
  612. Pitts D., Bolser J., Rosenbek M. et al. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest. 2009; 135: 1301- 1308.
  613. van Hooren M.R., Baijens L.W., Voskuilen S., et al. Treatment effects for dysphagia in Parkinson's disease: a systematic review.Parkinsonism & related disorders. 2014; 20(8):800–807.
  614. Warnecke I., Suttrup J.B., Schroder N., et al. Dziewas Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test Parkinsonism Relat. Disord. 2016; 28: 100-106
  615. Lim A., Leow L., Huckabee M.L., et al. A pilot study of respiration and swallowing integration in Parkinson's disease: “on” and “off” levodopa. Dysphagia. 2008; 23:76– 81.
  616. Hunter P.C., Crameri J., Austin S., et al. Response of parkinsonian swallowing dysfunction to dopaminergic stimulation. J Neurol Neurosurg Psychiatry. 1997; 63: 579–583.
  617. Hirano M., Isono C., Sakamoto H., et al. Rotigotine transdermal patch improves swallowing in dysphagic patients with Parkinson's disease. Dysphagia. 2015; 30: 452-456.
  618. Yu H., Takahashi K., Bloom L., et al. Effect of Deep Brain Stimulation on Swallowing Function: A Systematic Review. Front Neurol. 2020; 11:547.
  619. Kluger BM, Fox S, Timmons S, Katz M, Galifianakis NB, Subramanian I, Carter JH, Johnson MJ, Richfield EW, Bekelman D, Kutner JS, Miyasaki J. Palliative care and Parkinson's disease: Meeting summary and recommendations for clinical research. Parkinsonism Relat Disord. 2017 Apr;37:19-26. doi: 10.1016/j.parkreldis.2017.01.008. Epub 2017 Jan 11. PMID: 28108265.
  620. Oliver D, Borasio GD, Caraceni A, de Visser M, Grisold W, Lorenzl S, Veronese S, Voltz R.A. Consensus review on the development of palliative care for patients with chronic and progressive neurological disease Eur J Neurol. 2016 Jan;23(1):30-8 doi: 10.1111/ene.12889. Epub 2015 Oct 1
  621. The GSF Proactive Identification Guidance (PIG) 2016 vs6 © The Gold Standards Framework Centre in End of Life Care. Accessed 1 December 2017.
  622. Lugassy M. A palliative care approach to Parkinson’s and other neurodegenerative diseases. National Hospice and Palliative Care Organization Palliative Care Resource Series. Copyright © 2016 National Hospice and Palliative Care Organization
  623. Lau F, Downing M, Lesperance M, et al. Using the Palliative Performance Scale to provide meaningful survival estimates. J Pain Symptom Manage 2009;38:134-44
  624. Richfield EW, Jones EJ, Alty JE Palliative care for Parkinson's disease: a summary of the evidence and future directions. Palliat Med. 2013 Oct; 27(9):805-10. doi: 10.1177/0269216313495287
  625. Anneser J., Arenz V., and G. Domenico Borasio. Neurological Symptoms in Palliative Care Patients. Front Neurol. 2018; 9: 275. doi: 10.3389/fneur.2018.00275
  626. Colin W Campbell, Edward JS Jones, Jane Merrills, Hull Royal. Palliative and end-of-life care in advanced Parkinson’s disease and multiple sclerosis. Clinical Medicine 2010, Vol 10, No 3: 290–2. DOI: 10.7861/clinmedicine.10-3-290
  627. Isabel Boersma, Janis Miyasaki, Jean Kutner, Benzi Kluger. Palliative care and neurology Time for a paradigm shift. Neurology. 2014 Aug 5;83(6):561-7. doi: 10.1212/WNL.0000000000000674
  628. Bloem BR, Darweesh SKL, Meinders MJ. Palliative Programs for Persons With Parkinsonism-The Next Frontier. JAMA Neurol. 2020 May 1;77(5):548-550. doi: 10.1001/jamaneurol.2019.4697. PMID: 32040140
  629. Klietz M, Tulke A, Müschen LH, Paracka L, Schrader C, Dressler DW, Wegner F. Impaired Quality of Life and Need for Palliative Care in a German Cohort of Advanced Parkinson's Disease Patients. Front Neurol. 2018 Mar 6;9:120. doi: 10.3389/fneur.2018.00120. PMID: 29559949; PMCID: PMC5845640.
  630. Kluger BM, Shattuck J, Berk J, Sebring K, Jones W, Brunetti F, Fairmont I, Bowles DW, Sillau S, Bekelman DB. Defining Palliative Care Needs in Parkinson's Disease. Mov Disord Clin Pract. 2018 Nov 16;6(2):125-131. doi: 10.1002/mdc3.12702. PMID: 30838311; PMCID: PMC6384178.
  631. Tarolli CG, Holloway RG. Palliative care and Parkinson's disease: outpatient needs and models of care over the disease trajectory. Ann Palliat Med. 2020 Feb;9(Suppl 1):S44- S51. doi: 10.21037/apm.2019.11.11. Epub 2019 Dec 13. PMID: 31865745.
  632. Kwok JYY, Huang TW, Tretriluxana J, Auyeung M, Chau PH, Lin CC, Chan HYL. Symptom Burden and Unmet Support Needs of Patients With Parkinson's Disease: A Cross-Sectional Study in Asia-Pacific regions. J Am Med Dir Assoc. 2020 Oct 22:S1525- 8610(20)30795-7. doi: 10.1016/j.jamda.2020.09.012. Epub ahead of print. PMID: 33268298.
  633. Приказ Минздрава России N 345н, Минтруда России N 372н от 31.05.2019 "Об утверждении Положения об организации оказания паллиативной медицинской помощи, включая порядок взаимодействия медицинских организаций, организаций социального обслуживания и общественных объединений, иных некоммерческих организаций, осуществляющих свою деятельность в сфере охраны здоровья" Зарегистрировано в Минюсте России 26 июня 2019 г. N 55053
  634. Порядок оказания медицинской помощи взрослому населению при заболеваниях нервной системы (утв. приказом Министерства здравоохранения Российской Федерации от 15 ноября 2012 г. № 926н)
  635. Приказ Министерства здравоохранения Российской Федерации от 15 ноября 2012 г. № 931н "Об утверждении Порядка оказания медицинской помощи взрослому населению по профилю "нейрохирургия"
  636. Приказ Департамента здравоохранения города Москвы от 28.08.2017 № 605 «Об организации оказания паллиативной медицинской помощи взрослому населению
  637. Allen NE, Canning CG, Sherrington C, Lord SR, Latt MD, Close JC et al. The effects of an exercise program on fall risk factors in people with Parkinson's disease: a randomized controlled trial. Mov Disord 2010; 25(9):1217-1225.
  638. Ashburn A, Fazakarley L, Ballinger C, Pickering R, McLellan LD, Fitton C. A randomised controlled trial of a home-based exercise programme to reduce the risk of falling among people with Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78(7):678-684.
  639. Bridgewater KJ, Sharpe M. Trunk muscle training and early parkinson's disease. Physiother Th Pract 1997; 13(2):139-153.
  640. Caglar AT, Gurses HN, Mutluay FK, Kiziltan G. Effects of home exercises on motor performance in patients with Parkinson's disease. Clin Rehabil 2005; 19(8):870-877.
  641. Chandler C, Plant R. A targeted physiotherapy service for people with Parkinson's disease from diagnosis to end stage: a pilot study. In: Percival R, Hobson P, editors. Parkinson's disease: Studies in psychological and social care. Leicester: BPS Books; 1999. 256-269.
  642. Comella CL, Stebbins GT, Brown-Toms N, Goetz CG. Physical therapy and Parkinson's disease: a controlled clinical trial. Neurology 1994; 44(3 Pt 1):376-378.
  643. Cruise KE, Bucks RS, Loftus AM, Newton RU, Pegoraro R, Thomas MG. Exercise and Parkinson's: benefits for cognition and quality of life. Acta Neurol Scand 2011; 123(1):13-19.
  644. Dibble LE, Hale TF, Marcus RL, Droge J, Gerber JP, LaStayo PC. High-intensity resistance training amplifies muscle hypertrophy and functional gains in persons with Parkinson's disease. Mov Disord 2006; 21(9):1444-1452.
  645. Dibble LE, Hale TF, Marcus RL, Gerber JP, LaStayo PC. High intensity eccentric resistance training decreases bradykinesia and improves Quality Of Life in persons with Parkinson's disease: a preliminary study. Parkinsonism Relat Disord 2009; 15(10):752-757.
  646. Ebersbach G, Ebersbach A, Edler D, Kaufhold O, Kusch M, Kupsch A et al. Comparing exercise in Parkinson's disease--the Berlin LSVT(R)BIG study. Mov Disord 2010; 25(12):1902-1908.
  647. Ellis T, de Goede CJ, Feldman RG, Wolters EC, Kwakkel G, Wagenaar RC. Efficacy of a physical therapy program in patients with Parkinson's disease: A randomized controlled trial. Arch Phys Med Rehabil 2005; 86(4):626-632.
  648. Fisher BE, Wu AD, Salem GJ, Song J, Lin CH, Yip J et al. The effect of exercise training in improving motor performance and corticomotor excitability in people with early Parkinson's disease. Arch Phys Med Rehabil 2008; 89(7):1221-1229.
  649. Goodwin VA, Richards SH, Henley W, Ewings P, Taylor AH, Campbell JL. An exercise intervention to prevent falls in people with Parkinson's disease: a pragmatic randomised controlled trial. J Neurol Neurosurg Psychiatry 2011; 82(11):1232-1238.
  650. Hass CJ, Buckley TA, Pitsikoulis C, Barthelemy EJ. Progressive resistance training improves gait initiation in individuals with Parkinson's disease. Gait Posture 2012; 35(4):669-673.
  651. Hirsch MA, Toole T, Maitland CG, Rider RA. The effects of balance training and high-intensity resistance training on persons with idiopathic Parkinson's disease. Arch Phys Med Rehabil 2003; 84(8):1109-1117.
  652. Klassen L, Dal Bello-Haas V, Sheppard M, Metcalfe A. Evaluating the benefits of group exercise and group exercise and education programs for individuals with Parkinson's disease. Physiotherapy 2007; 93 (Suppl. 1):S91.
  653. Meek C, Sackley CM, Clarke C.E., Soundy AA, Winward C, Esser P et al. Long- term individual fitness enablement (LIFE) for Parkinson's disease:a feasibility study. Mov Disord 2010; 25 (Suppl 3):S713.
  654. Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res 2011; 2011:232473.
  655. Sage MD, Almeida QJ. Symptom and gait changes after sensory attention focused exercise vs aerobic training in Parkinson's disease. Mov Disord 2009.
  656. Schenkman M, Cutson TM, Kuchibhatla M, Chandler J, Pieper CF, Ray L et al. Exercise to improve spinal flexibility and function for people with Parkinson's disease: a randomized, controlled trial. J Am Geriatr Soc 1998; 46(10):1207-1216.
  657. Schenkman M, Hall DA, Baron AE, Schwartz RS, Mettler P, Kohrt WM. Exercise for people in early- or mid-stage Parkinson disease: a 16-month randomized controlled trial. Phys Ther 2012; 92(11):1395-1410.
  658. Schilling BK, Pfeiffer RF, LeDoux MS, Karlage RE, Bloomer RJ, Falvo MJ. Effects of moderate-volume, high-load lower-body resistance training on strength and function in persons with Parkinson's disease: a pilot study. Parkinsons Dis 2010; 2010:824734.
  659. Stozek J, Rudzinska M, Longawa K, Szczudlik A. [The effect of the complex rehabilitation on posture and gait in Parkinson disease]. Neurol Neurochir Pol 2003; 37 Suppl 5:67-81.
  660. Toole T, Hirsch MA, Forkink A, Lehman DA, Maitland CG. The effects of a balance and strength training program on equilibrium in Parkinsonism: A preliminary study. Neurorehabilitation 2000; 14(3):165-174.
  661. Winward C, Sackley C, Meek C, Izadi H, Barker K, Wade D et al. Weekly exercise does not improve fatigue levels in Parkinson's disease. Mov Disord 2012; 27(1):143- 146.
  662. Yousefi B, Tadibi V, Khoei AF, Montazeri A. Exercise therapy, quality of life, and activities of daily living in patients with Parkinson disease: a small scale quasi-randomised trial. Trials 2009; 10:67.
  663. Cakit BD, Saracoglu M, Genc H, Erdem HR, Inan L. The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease. Clin Rehabil 2007; 21(8):698-705.
  664. Canning CG, Allen NE, Dean CM, Goh L, Fung VS. Home-based treadmill training for individuals with Parkinson's disease: a randomized controlled pilot trial. Clin Rehabil 2012; 26(9):817-826.
  665. Frazzitta G, Maestri R, Uccellini D, Bertotti G, Abelli P. Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: A comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. Mov Disord 2009.
  666. Kurtais Y, Kutlay S, Tur BS, Gok H, Akbostanci C. Does treadmill training improve lower-extremity tasks in Parkinson disease? A randomized controlled trial. Clin J Sport Med 2008; 18(3):289-291.
  667. Miyai I, Fujimoto Y, Ueda Y, Yamamoto H, Nozaki S, Saito T et al. Treadmill training with body weight support: its effect on Parkinson's disease. Arch Phys Med Rehabil 2000; 81(7):849-852.
  668. Miyai I, Fujimoto Y, Yamamoto H, Ueda Y, Saito T, Nozaki S et al. Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2002; 83(10):1370-1373.
  669. Pohl M, Rockstroh G, Ruckriem S, Mrass G, Mehrholz J. Immediate effects of speed-dependent treadmill training on gait parameters in early Parkinson's disease. Arch Phys Med Rehabil 2003; 84(12):1760-1766.
  670. Protas EJ, Mitchell K, Williams A, Qureshy H, Caroline K, Lai EC. Gait and step training to reduce falls in Parkinson's disease. Neurorehabilitation 2005; 20(3):183-190.
  671. Yang YR, Lee YY, Cheng SJ, Wang RY. Downhill walking training in individuals with Parkinson's disease: a randomized controlled trial. Am J Phys Med Rehabil 2010; 89(9):706-714.
  672. Morris ME. Movement disorders in people with Parkinson disease: a model for physical therapy. Phys Ther 2000; 80(6):578-597.
  673. Behrman AL, Cauraugh JH, Light KE. Practice as an intervention to improve speeded motor performance and motor learning in Parkinson's disease. J Neurol Sci 2000; 174(2):127-136.
  674. Farley BG, Koshland GF. Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease. Experimental Brain Research 2005; 167(3):462-467.
  675. Jobges M, Heuschkel G, Pretzel C, Illhardt C, Renner C, Hummelsheim H. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75(12):1682-1687.
  676. Lewis GN, Byblow WD, Walt SE. Stride length regulation in Parkinson's disease: the use of extrinsic, visual cues. Brain 2000; 123 (Pt 10):2077-2090.
  677. Nieuwboer A, Rochester L, Muncks L, Swinnen SP. Motor learning in Parkinson's disease: limitations and potential for rehabilitation. Parkinsonism Relat Disord 2009; 15 Suppl 3:S53-S58.
  678. Platz T, Brown RG, Marsden CD. Training improves the speed of aimed movements in Parkinson's disease. Brain 1998; 121 ( Pt 3):505- 514.
  679. Earhart GM, Williams AJ. Treadmill training for individuals with Parkinson disease. Phys Ther 2012; 92(7):893-897.
  680. Mehrholz J, Friis R, Kugler J, Twork S, Storch A, Pohl M. Treadmill training for patients with Parkinson's disease. Cochrane Database Syst Rev 2010;(1):CD007830.
  681. Duncan RP, Earhart GM. Randomized controlled trial of community-based dancing to modify disease progression in Parkinson disease. Neurorehabil Neural Repair 2012; 26(2):132-143.
  682. Hackney ME, Kantorovich S, Levin R, Earhart GM. Effects of tango on functional mobility in Parkinson's disease: a preliminary study. J Neurol Phys Ther 2007; 31(4):173-179.
  683. Hackney ME, Earhart GM. Effects of dance on movement control in Parkinson's disease: a comparison of Argentine tango and American ballroom. J Rehabil Med 2009; 41(6):475-481.
  684. Hackney ME, Earhart GM. Effects of dance on gait and balance in Parkinson's disease: a comparison of partnered and nonpartnered dance movement. Neurorehabil Neural Repair 2010; 24(4):384-392.
  685. Mohr B, Muller V, Mattes R, Rosin R, Federmann B, Strehl U et al. Behavioral treatment of Parkinson's disease leads to improvement of motor skills and tremor reduction. Behav Ther 1996; 27:235-255.
  686. Tomlinson CL, Patel S, Meek C, Herd CP, Clarke CE, Stowe R et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev 2013; 9:CD002817.
  687. Volpe D, Signorini M, Marchetto A, Lynch T, Morris ME. A comparison of Irish set dancing and exercises for people with Parkinson's disease: a phase II feasibility study. BMC Geriatr 2013; 13:54.
  688. Frazzitta G, Maestri R, Uccellini D, Bertotti G, Abelli P. Rehabilitation treatment of gait in patients with Parkinson's disease with freezing: A comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training. Mov Disord 2009.
  689. Hackney ME, Earhart GM. Tai Chi improves balance and mobility in people with Parkinson disease. Gait Posture 2008; 28(3):456-460.
  690. Kurtais Y, Kutlay S, Tur BS, Gok H, Akbostanci C. Does treadmill training improve lower-extremity tasks in Parkinson disease? A randomized controlled trial. Clin J Sport Med 2008; 18(3):289-291.
  691. Li F, Harmer P, Fitzgerald K, Eckstrom E, Stock R, Galver J et al. Tai chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012; 366(6):511-519.
  692. Miyai I, Fujimoto Y, Ueda Y, Yamamoto H, Nozaki S, Saito T et al. Treadmill training with body weight support: its effect on Parkinson's disease. Arch Phys Med Rehabil 2000; 81(7):849-852.
  693. Miyai I, Fujimoto Y, Yamamoto H, Ueda Y, Saito T, Nozaki S et al. Long-term effect of body weight-supported treadmill training in Parkinson's disease: a randomized controlled trial. Arch Phys Med Rehabil 2002; 83(10):1370-1373.
  694. Pohl M, Rockstroh G, Ruckriem S, Mrass G, Mehrholz J. Immediate effects of speed-dependent treadmill training on gait parameters in early Parkinson's disease. Arch Phys Med Rehabil 2003; 84(12):1760-1766.
  695. Reuter I, Mehnert S, Leone P, Kaps M, Oechsner M, Engelhardt M. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease. J Aging Res 2011; 2011:232473.
  696. Shankar A, De Bruin N, Bonfield S, Derwent L, Eliasziw M, Hu B et al. Benefit of music therapy in patients with Parkinson's disease: a randomized controlled trial. Mov Disord 2008; 23((Suppl 1)):68.
  697. Yang YR, Lee YY, Cheng SJ, Wang RY. Downhill walking training in individuals with Parkinson's disease: a randomized controlled trial. Am J Phys Med Rehabil 2010; 89(9):706-714.
  698. Morris ME. Movement disorders in people with Parkinson disease: a model for physical therapy. Phys Ther 2000; 80(6):578-597.
  699. Behrman AL, Cauraugh JH, Light KE. Practice as an intervention to improve speeded motor performance and motor learning in Parkinson's disease. J Neurol Sci 2000; 174(2):127-136.
  700. Farley BG, Koshland GF. Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease. Experimental Brain Research 2005; 167(3):462-467.
  701. Jobges M, Heuschkel G, Pretzel C, Illhardt C, Renner C, Hummelsheim H. Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2004; 75(12):1682-1687.
  702. Lewis GN, Byblow WD, Walt SE. Stride length regulation in Parkinson's disease: the use of extrinsic, visual cues. Brain 2000; 123 ( Pt 10):2077-2090.
  703. Platz T, Brown RG, Marsden CD. Training improves the speed of aimed movements in Parkinson's disease. Brain 1998; 121 ( Pt 3):505- 514.
  704. Van der Eijk M, Faber MJ, Al SS, Munneke M, Bloem BR. Moving towards patient-centered healthcare for patients with Parkinson's disease. Parkinsonism Relat Disord 2011; 17(5):360-364.
  705. Kamsma YPT, Brouwer WH, Lakke JPWF. Training of compensatory strategies for impaired gross motor skills in patients with Parkinson's disease. Physiother Th Pract 1995; 11:209-229.
  706. Keus SH, Bloem BR, van Hilten JJ, Ashburn A, Munneke M. Effectiveness of physiotherapy in Parkinson's disease: the feasibility of a randomised controlled trial. Parkinsonism Relat Disord 2007; 13(2):115-121.
  707. Mohr B, Muller V, Mattes R, Rosin R, Federmann B, Strehl U et al. Behavioral treatment of Parkinson's disease leads to improvement of motor skills and tremor reduction. Behav Ther 1996; 27:235-255.
  708. Morris ME, Iansek R, Kirkwood B. A randomized controlled trial of movement strategies compared with exercise for people with Parkinson's disease. Mov Disord 2009; 24(1):64-71.
  709. Nieuwboer A, De Weerdt W, Dom R, Truyen M, Janssens L, Kamsma Y. The effect of a home physiotherapy program for persons with Parkinson's disease. J Rehabil Med 2001; 33(6):266-272.
  710. Stozek J, Rudzinska M, Longawa K, Szczudlik A. [The effect of the complex rehabilitation on posture and gait in Parkinson disease]. Neurol Neurochir Pol 2003; 37 Suppl 5:67-81.
  711. Morris ME. Movement disorders in people with Parkinson disease: a model for physical therapy. Phys Ther 2000; 80(6):578-597.
  712. Reuter I, Mehnert S, Sammer G, Oechsner M, Engelhardt M. Efficacy of a multimodal cognitive rehabilitation including psychomotor and endurance training in Parkinson's disease. J Aging Res 2012; 2012:235765.
  713. van Eijkeren, F. Nordic Walking Improves Mobility in Parkinson’s Disease / F. van Eijkeren, R. Reijmers, M. Kleinveld [et al.]// Mov Disord. – 2008. – Vol. 23, № 15. – P. 2239–2243.
  714. Atterbury, E. Balance training in individuals with Parkinson's disease: therapist- supervised vs. home-based exercise programme/ E. Atterbury, E. K. Welman// Gait Posture. – 2017. – Vol.55. - P.138-144.
  715. Rochester, L. Targeting dopasensitive and dopa-resistant gait dysfunction in Parkinson’s disease: selective responses to internal and external cues/ L. Rochester, K. Baker, Nieuwboer, A. D. Burn// Mov Disord. - 2011. - Vol.26. - P.430–435.
  716. Hausdorff, J.M. Gait dynamics, fractals and falls: finding meaning in the stride-to- stride fluctuations of human walking/ J.M. Hausdorff // Hum Mov Sci. -2007. - Vol.26. - P.555– 589.
  717. Frazzitta, G. Rehabilitation treatment of gait in patients with Parkinson’s disease with freezing: a comparison between two physical therapy protocols using visual and auditory cues with or without treadmill training/ G. Frazzitta, R. Maestri, D. Uccellini [et al.] // Mov Disord. - 2009. - Vol.24. - P.1139–1143.
  718. Donovan, S. Laserlight cues for gait freezing in Parkinson’s disease: an open-label study/S. Donovan, C. Lim, N. Diaz [et al.] // Parkinsonism Relat Disord. -2011. - Vol.17. - P. 240–245.
  719. Reuter, I. Effects of a flexibility and relaxation programme, walking, and nordic walking on Parkinson's disease/I. Reuter, S. Mehnert, P. Leone [et al.] // J Aging Res. -2011. - P. 1-18.
  720. Kalf, H., de Swart, B., et al. Guidelines for Speech-Language Therapy in Parkinson’s Disease Nijmegen (The Netherlands); Miami (U.S.A.): ParkinsonNet (The Netherlands); National Parkinson Foundation (U.S.A.), (2011), 1-137.
  721. Deuschl, G, Herzog J, Kleiner-Fisman G, Kubu C , M. Lozano, E. Lyons ,Maria C. Rodriguez-Oroz ,Filippo Tamma ,Alexander I. Tröster ,Jerrold L. Vitek , Jens Volkmann J, Voon V. Deep brain stimulation: Postoperative issues//Mov Disord. 2006 Jun;21 Suppl 14:S219- 37.
  722. Приказ Минздрава России от 15.11.2012 №926н «Об утверждении Порядка оказания медицинской помощи взрослому населению при заболеваниях нервной системы» (зарегистрирован в Минюсте России 23.01.2013 №26692)
  723. Приказ Министерства здравоохранения Российской Федерации от 28 сентября 2020 г. N 1029н «Об утверждении перечней медицинских показаний и противопоказаний для санаторно-курортного лечения» http://publication.pravo.gov.ru/Document/View/0001202010270044.
  724. Trosch RM et al. Clozapine use in Parkinson’s disease: a retrospective analysis of a large multicentered clinical experience//Movement disorders.-1998.-T.13.-№3.-C.377-382.
  725. Катунина, Е.А. Применение препарата допа и ее производные в лечении болезни Паркинсона/Е.А. Катунина, Г.Н. Авакян, Ю.Н. Бездольный//Эффективная фармакотерапия.-2010.-№17.-С.12-19.
  726. Cutsforth JK, Low PA Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer Neurol Ther. 2019 Dec; 8(2): 307–324 doi: 10.1007/s40120-019-00152-9
  727. ThorpyMJ. Sleep disorders in Parkinson’s disease. Clin Cornerstone. 2004;6 Suppl 1A:S7-15. doi: 10.1016/s1098-3597(04)90013-0. PMID:15259535.
  728. Нодель М.Р., Яхно Н.Н. Утомляемость при болезни Паркинсона. Неврологический Журнал. 2017;5:244-251.
  729. Razmy A., Lang A.E., Shapiro C.M. Predictors of impaired daytime sleep and wakefulness in patients with parkinsons disease treated with ergot vs nonergot dopamine agonists. Arch. Neurol.2004; 61: 97–102.
  730. Metzer WS, Paige SR, Newton JE. Inefficacy of propranolol in attenuation of drug- induced parkinsonian tremor. Mov Disord. 1993;8(1):43-6. doi: 10.1002/mds.870080108. PMID: 8093548.
  731. Levin OS, Chimagomedova ASh, Skripkina NA, Lyashenko EA, Babkina OV. Nonmotor Symptoms in Vascular and Other Secondary Parkinsonism. International review of neurobiology. 2017;134:1303-1334.
  732. Карабань И.Н. Сосудистый паркинсонизм: возможность и/или объективная реальность // Междунар. неврол. журн.; МНЖ. 2016. №3 (81). URL: https://cyberleninka.ru/article/n/sosudistyy-parkinsonizm-vozmozhnost-i-ili-obektivnaya- realnost (дата обращения: 02.10.2021).
  733. Юдина, В.В. Диагностика и лечение сосудистого паркинсонизма / В. В. Юдина, О. Н. Воскресенская, Г. К. Юдина // Саратовский научно-медицинский журнал. – 2010. – Т. 6. – № 1. C. 120-123.
  734. Coon E.A., Ahlskog J.E. My Treatment Approach to Multiple System Atrophy //Mayo Clinic Proceedings. – Elsevier, 2021. – Т. 96. – №. 3. C. 708-719.
  735. Coon E.A., Ahlskog J.E. My Treatment Approach to Multiple System Atrophy //Mayo Clinic Proceedings. – Elsevier, 2021. – Т. 96. – №. 3. C. 708-719
  736. Rondot P., Ziegler M. Activity and acceptability of piribedil in Parkinson's disease: a multicentre study //Journal of neurology. – 1992. – Т. 239. – №. 1. C. S28-S34.
  737. Pena E. et al. Antidepressants in Parkinson's disease. Recommendations by the movement disorder study group of the Neurological Association of Madrid //Neurología (English Edition). – 2018. – Т. 33. – №. 6. C. 395-402.
  738. Larsen J. P., Tandberg E. Sleep disorders in patients with Parkinson’s disease //CNS drugs. – 2001. – Т. 15. – №. 4. C. 267-275.
  739. Juncos J. L. et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease //Movement Disorders. – 2004. – Т. 19. – №. 1. C. 29-35.
  740. Mamikonyan E. et al. Rivastigmine for mild cognitive impairment in Parkinson disease: a placebo‐controlled study //Movement Disorders. – 2015. – Т. 30. – №. 7. C. 912-918.
  741. Nashatizadeh M.M, Lyons K.E., Pahwa R. A review of ropinirole prolonged release in Parkinson’s disease//Clin Interv Aging. 2009; 4: 179–186.
  742. Crosby N.J., Deane K.H., Clarke C.E. Beta-blocker therapy for tremor in Parkinson's disease//Cochrane Database Syst Rev. 2003;(1):CD003361.
  743. Jost W.H. Use of Botulinum Neurotoxin in Parkinson’s Disease: A Critical Appraisal// Toxins (Basel). 2021 Feb; 13(2): 87.
  744. Batla A. et al. Treatment options for urogenital dysfunction in Parkinson’s disease //Current treatment options in neurology. – 2016. – Т. 18. – №. 10. C. 1-13.
  745. Ondo W. G. et al. Memantine for non-motor features of Parkinson’s disease: a double-blind placebo controlled exploratory pilot trial //Parkinsonism & related disorders. – 2011. – Т. 17. – №. 3. C. 156-159.
  746. Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease //New England Journal of Medicine. – 1999. – Т. 340. – №. 10. C. 757-763.
  747. Merims D. et al. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis //Clinical neuropharmacology. – 2006. – Т. 29. – №. 6. C. 331- 337.
  748. Shvarts P. G. et al. Experience with application of trospium chloride in patients with neurogenic detrusor overactivity //Urologiia (Moscow, Russia: 1999). – 2009. – №. 5. C. 24-29.
  749. Moro A. et al. Delusional misidentification syndrome and other unusual delusions in advanced Parkinson's disease //Parkinsonism & related disorders. – 2013. – Т. 19. – №. 8. C. 751-754.
  750. Goldman J. G. Treatment of Dementia in Parkinson’s Disease //Therapy of Movement Disorders. – Humana, Cham, 2019. C. 99-102.
  751. Aiken C. B. et al. Pramipexole in psychiatry: a systematic review of the literature //Journal of Clinical Psychiatry. – 2007. – Т. 68. – №. 8. C. 1230-1236.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*